Virginia Commonwealth University

VCU Scholars Compass
Theses and Dissertations

Graduate School

2013

Understanding Molecular Interactions: Application of HINT-based
Tools in the Structural Modeling of Novel Anticancer and Antiviral
Targets, and in Protein-Protein Docking
Hardik Parikh
Virginia Commonwealth University

Follow this and additional works at: https://scholarscompass.vcu.edu/etd
Part of the Pharmacy and Pharmaceutical Sciences Commons
© The Author

Downloaded from
https://scholarscompass.vcu.edu/etd/3116

This Dissertation is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It
has been accepted for inclusion in Theses and Dissertations by an authorized administrator of VCU Scholars
Compass. For more information, please contact libcompass@vcu.edu.

© Hardik I. Parikh
2013
All Rights Reserved

UNDERSTANDING MOLECULAR INTERACTIONS: APPLICATIONS OF HINT-BASED
TOOLS IN THE STRUCTURAL MODELING OF NOVEL ANTICANCER AND
ANTIVIRAL TARGETS, AND IN PROTEIN-PROTEIN DOCKING

A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor
of Philosophy at Virginia Commomwealth University

by
Hardik I. Parikh
Bachelor of Pharmacy, University of Pune, India, 2007
Director: Dr. Glen E. Kellogg, Ph. D.
Associate Professor,
Department of Medicinal Chemistry

Virginia Commomwealth University
Richmond, Virgina
May 2013

	
  

ii

	
  

iii

ACKNOWLEDGMENT

This dissertation would not have been possible without the guidance, help and
support of several individuals. It is my pleasure to convey my gratitude to them all.
I would like to express my deepest appreciation, first and foremost, to my
advisor, Dr. Glen E. Kellogg, for his absolute support, supervision and innovative ideas
during the course of my graduate studies. The past five years have been a great
learning experience for me, and I shall carry the lessons with me throughout my life. I
am extremely fortunate to have him as my advisor. I am thankful to him for patiently
correcting my writing, and also for financially supporting my research work. Without his
guidance, patience and persistent help, this dissertation would have remained a dream.
My parents, Mr. Ishwar S. Parikh and Mrs. Amita I. Parikh, have always been
there to support me in times of need. Thank you both for your unconditional love and
encouragement at every stage of my life. I dedicate this work to them. My sister Mrs.
Harshal A. Patwa and my brother-in-law Mr. Aanak G. Patwa deserve my wholehearted
thanks as well. I would also like to thank members of my extended family for their best
wishes.

	
  

iv
I gratefully acknowledge Dr. Shijun Zhang, Dr. Michael A. McVoy, Dr. Umesh R.

Desai and Dr. H. Tonie Wright for serving as members of my graduate student
committee. I thank them for taking time out of their busy schedules for reviewing and
evaluating my research. I am grateful for their helpful insights and invaluable
suggestions throughout.
I would also like to thank current and former members of Kellogg’s Molecular
Modeling and Drug Design Group for sharing their research skills and experiences with
me, in particular Dr. Aurijit Sarkar, Dr. Ashutosh Tripathi, Dr. Vishal Koparde, Dr. Philip
Mosier, Dr. Alexander Bayden, Chenxiao “Max” Da, Saheem Zaidi, Mostafa Ahmed,
and Jeremy Chojnacki.
My friends have helped me stay sane through these difficult years. Their love,
care and support have helped me stay focused on my graduate studies. I would like to
thank Swati, Kushal, Shreyas, Aagam, Dhawal, Mayank, Manali and Sayali, who have
always been there for me. Words are not enough to acknowledge their influence in my
life.
It gives me immense pleasure to thank all my friends in Richmond, especially
Atul, Rio, Akul, Sweety, Shrenik, Pratik, Soumya, Khushboo, Shilpa, Priyanka, Suditi,
Farhana, Tanvi, Divya, Batul, Shrinal, Arvind, Harshad, Shankar, Dipen, Jayul,
Soundarya, Vidya, Della, Rajkumar, Jigar, Ronak, Rakesh, Dharik, Jugal and Vivek for
being a family away from home. It is because of them that my graduate experience has
been one that I will cherish forever. Thank you all!

	
  

v
Finally, I would like to acknowledge the School of Pharmacy, VCU for giving me

the opportunity to undertake my graduate studies. I would also like to thank the VCU
Graduate School for the 2012-2013 Thesis/Dissertation Assistantship for providing the
financial support for the final year of my graduate studies.
Thank you, Lord, for always being there for me.

	
  

vi

TABLE OF CONTENTS

Acknowledgment……………………………………………………………………………….. iii
List of Tables…………………………………………………………………………………..... x
List of Figures………………………………………………………………………………….. xii
Abstract…………………………………………………………………………………………. xv
Chapter 1: Introduction
1.1

The hydrophobic effect…………………………………………………………...….1

1.2

Molecular interactions………………………………………………………………..3

1.3

Interfacial structural waters…………………………………………………………. 8

1.4

Free energy and binding affinity…………………………………………………….9
1.4.1

Experimental measurement of binding free energy………......…... 12

1.4.2

Theoretical calculation of binding free energy……………….......... 13

1.5

The HINT (Hydropathic INTeractio) Model…...………………......……………...14

1.6

Research plan……………………………………………………………………….23

Chapter 2: Thiazolidine-2,4-dione (TZD) analogue K145 – Selective SphK2 inhibitor
2.1

Introduction…………………………………………………………………………. 32
2.1.1

Sphingolipids – Structure and function………………………………….32

2.1.2

Sphingosine kinases and cancer……………...…………………………36

	
  

vii
2.1.3

Thiazolidine-2,4-dione analogue K145 – Selective SphK2 inhibitor... 41

2.1.4

Sphingosine kinase C4 domain – A putative sphingosine-binding
domain……………..……………………………………………………….44

2.1.5
2.2

2.3

2.4

Specific aim………………………………………......…………………... 47

Methods……………………………………………………………………………... 48
2.2.1

Structural modeling of SphK1 and SphK2……………………………... 48

2.2.2

Inhibitor docking…………………………………………………………...49

Results and Discussion………………….………………………………………....50
2.3.1

Structural modeling of SphK1 and SphK2……………………………... 50

2.3.2

Model validation by inhibitor docking……...………………………….... 54

2.3.3

Proposed binding mode for K145……….......…………………………..57

Conclusion…….………………………………………......................................... 59

Chapter 3: Homology modeling of human cytomegalovirus alkaline nuclease UL98 and
identification of potential leads by virtual screening
3.1

3.2

Introduction………………………………........................................................... 65
3.1.1

Human cytomegalovirus (HCMV) – A human pathogen……………... 65

3.1.2

Antiviral therapy for CMV infections…………................................... 67

3.1.3

HCMV alkaline nuclease UL98 – A novel target……………………….72

3.1.4

Alkaline nucleases – Structural insights………………………………...74

3.1.5

Specific aims……………………………………………………………….77

Methods………………………………................................................................ 78
3.2.1

Structural modeling of HCMV UL98 AN……………............................ 78

	
  

viii

3.3

3.2.2

Validation of UL98 AN model using mutagenesis............................... 83

3.2.3

3D virtual screening on the active site of UL98 AN model…………....83

Results and Discussion………......................................................................... 86
3.3.1

The template – Kaposi’s sarcoma associated Shut-off and
exonuclease (KSHV–SOX)................................................................. 86

3.4

3.3.2

HCMV UL98 AN model…………………………………….....................88

3.3.3

Validation of UL98 AN model using mutagenesis…………………….. 98

3.3.4

3D virtual screening hits....................................................................103

Conclusion..................................................................................................... 110

Chapter 4: Inclusion of “Relevant” interfacial waters improve protein-protein docking
predictions
4.1

Introduction………………………………......................................................... 116
4.1.1

Protein-protein interactions: Need for computational prediction
tools…............................................................................................... 116

4.2

4.1.2

Protein-protein docking: The process………...….............................. 118

4.1.3

Current protein-protein docking algorithms……...…………………… 121

4.1.4

Solvated docking……………………………………………………..…. 122

4.1.5

Explicit hydropathic approach…………………………………………. 128

4.1.6

Specific aim……………………………………………………………… 130

Methods…………………................................................................................ 132
4.2.1

Data set…………………………………………………………………...132

4.2.2

Determination of “bridging” interfacial waters………………………... 132

	
  

ix

4.3

4.2.3

Solvated docking using ZDOCK………………………………………. 135

4.2.4

The assessment protocol…………………………………………….....136

Results……..……………................................................................................ 141
4.3.1

Data set…………………...………………………………………………141

4.3.2

ZDOCK – A rigid body docking program…………………...………… 143

4.3.3

HINT scores predict correct geometry...……………………………… 143

4.3.4

Unsolvated docking vs Solvated docking…...……………...…………145

4.4

Discussion......................................................................................................162

4.5

Conclusion……………………………..............................................................176

Chapter 5: Conclusions……………………………………………………………………... 183
Appendix A.1

The Clustal X color scheme……………………………………………...188

Vita…………………………………………………………………………………………….. 189

x

LIST OF TABLES

1.1 𝑇!" interaction matrix ……….......………………………………………………………..17
1.2 Types of atom-atom interactions characterized and scored by HINT force
field…………………………………………………………………………….…………. 20
2.1

HINT scores of the docked molecules into the C4 domain of SphK1 and
SphK2…………………….……………………………………………………………… 56

2.2

HINT scores for K145 docked into the C4 domain of SphK1 and SphK2…………58

3.1

Summary of currently licensed antivirals for CMV infections……………………….69

3.2

𝐻!"!#$ scores and corresponding ΔΔ𝐺!"#$"#% energies calculated for
wild-type and UL98 AN mutants………..…………………………………………….. 96

3.3

Top 15 hits from virtual screening…………………………………………………… 107

4.1

Protein-protein docking softwares: Characteristics, advantages and
disadvantages…………………………………………………………………………. 123

4.2

Predicted model quality classification criteria……………………………………… 140

4.3

Solvated protein-protein docking data set……………………...…………………...142

4.4

Hit-count for top N predictions for different docking protocols……….……………150

4.5

Comparison of average hit-count for different docking protocols………………... 151

4.6

Weighted-score for top N predictions for different docking protocols…….………155

xi
4.7

Comparison of weighted-score for different docking protocol…….……………… 156

4.8

Count of high-accuracy (***) models in top N predictions…………..……………. 160

4.9

HINT water Relevance report for interfacial waters in Anti-Lysozyme
antibody HyHEL-63–Lysozyme HEL complex crystal structure………………... 165

4.10 Unsolvated docking results for HyHEL-63–HEL complex………………………. 168
4.11 Solvated docking results for HyHEL-63–HEL complex…………………………... 169

xii
LIST OF FIGURES

1.1 Correlation between calculated HINT scores and measured free energy of
binding for 76 diverse protein-ligand complexes…..………………………………... 21
2.1

General structures of common sphingolipids………..………………………………. 33

2.2

Scheme showing the participation of bioactive sphingolipids –
ceramide, sphingosine and sphingosine-1-phosphate in cell biology...……………35

2.3

The sphingosine rheostat: Cell fate determinant………………………….………… 36

2.4

Summary of role of S1P in cancer……………………………………………………. 39

2.5

Structures of known SphK2 selective inhibitors….…………………………………..40

2.6

Overlay of K145 with sphingosine……………………………………………………..43

2.7

Biochemical assays showing K145 as a selective, substrate-competitive
SphK2 inhibitor………………………………………………………………………….. 43

2.8

Schematic representation of human sphingosine kinases…………………………. 45

2.9

Relative sphingosine kinase activities of mouse SphK1a mutants………………...45

2.10 Sequence alignment of the C4 domain of sphingosine kinases……………….….. 46
2.11 Overall fold of the template structure – Diacylglycerol kinase from Bascillus
anthracis str. Sterne (PDB ID: 3t5p)…………………………………………….……. 51
2.12 Sequence alignment of SphK1 with the template 3t5p………………………..…….52
2.13 Sequence alignment of SphK2 with the template 3t5p………………………..…….53
2.14 Structural models of SphK1 (A) and SphK2 (B)………………………………..…….55

xiii
2.15 Binding mode of K145 in C4 domain of SphK1 (A) and SphK2 (B)…….………….58
3.1

Antivirals for cytomegalovirus infections…………………………………………...… 68

3.2

The conserved PD-(D/E)XK core fold with active site formation…………………...76

3.3

Template structure – KSHV-SOX (PDB ID: 3fhd)……………………………………87

3.4

UL98 AN sequence in pairwise alignment with KSHV – SOX……………………...89

3.5

Ramachandran plots for UL98 AN homology model………………………………...91

3.6

UL98 AN model…………………………………………………………………………. 92

3.7

UL98 AN active site model………………………………………………………......... 94

3.8

Multiple sequence alignment between Herpesvirus alkaline nucleases………….. 95

3.9

Active site models for DNA interactions of wild-type and mutant UL98 AN……… 97

3.10 UL98 AN mutants – Exo activity……………………………………………………...100
3.11 UL98 AN mutants – Endo activity…………………………………………………… 101
3.12 Pharmacophore model……………………………………………………………….. 105
3.13 Structures of virtual screening hits (top 15)………………………………………… 108
3.14 Binding mode of hit NSC120634……………………………………………………..109
4.1

Schematic illustration of residue-residue contact pairs…..………………………. 139

4.2

Schematic illustration of ligand and interface RMSDs……………………………..139

4.3

Scatterplot showing positive linear correlation between scaled HINT scores
and fnat values of all predictions for each test case………………………............ 146

4.4

Scatterplot of fnat vs scaled HINT scores for top 10 and lowest 10 predictions...147

4.5a Number of hits in the top N predictions in unsolvated and solvated docking…....152
4.5b Difference in number of hits in the top N predictions in unsolvated and

xiv
solvated docking………………………………………………………………………. 153
4.6

Comparison of average hit-count in top N predictions for unsolvated and
solvated docking………………………………………………………………………. 154

4.7a Weighted-score for the top N predictions in unsolvated and solvated docking....157
4.7b Difference in number of weighted-score for the top N predictions in
unsolvated and solvated docking…………………………………………………… 158
4.8

Comparison of average weighted-score in top N predictions for unsolvated
and solvated docking…………………………………………………………………. 159

4.9

Scatterplot of i-RMSD vs scaled HINT scores for all predictions obtained from
solvated docking, grouped based on their quality…………………………………. 163

4.10 Crystal structure of anti-lysozyme antibody HyHEL-63–Lysozyme HEL
complex (PDB ID: 1dqj)………………………………………………………………. 166
4.11 Bridging interactions formed by Relevant interfacial water HOH 143…………… 171
4.12 Unsolvated docking results for HyHEL-63–HEL complex……………..…………. 172
4.13 Solvated docking results for HyHEL-63–HEL complex……………………...……. 173

	
  

xv

ABSTRACT

UNDERSTANDING MOLECULAR INTERACTIONS: APPLICATIONS OF HINT-BASED
TOOLS IN THE STRUCTURAL MODELING OF NOVEL ANTICANCER AND
ANTIVIRAL TARGETS, AND IN PROTEIN-PROTEIN DOCKING
By Hardik I. Parikh, Ph. D.
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor
of Philosophy at Virginia Commomwealth University
Virginia Commomwealth University, 2013
Major Director: Dr. Glen E. Kellogg, Ph. D.
Associate Professor, Department of Medicinal Chemistry

Computationally driven drug design/discovery efforts generally rely on accurate
assessment of the forces that guide the molecular recognition process. HINT
(Hydropathic INTeraction) is a natural force field, derived from experimentally
determined partition coefficients that quantifies all non-bonded interactions in the
biological environment, including hydrogen bonding, electrostatic and hydrophobic
interactions, and the energy of desolvation. The overall goal of this work is to apply the
HINT-based atomic level description of molecular systems to biologically important
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proteins, to better understand their biochemistry – a key step in exploiting them for
therapeutic purposes.
This dissertation discusses the results of three diverse projects: i) structural
modeling of human sphingosine kinase 2 (SphK2, a novel anticancer target) and
binding mode determination of an isoform selective thiazolidine-2,4-dione (TZD) analog;
ii) structural modeling of human cytomegalorvirus (HCMV) alkaline nuclease (AN) UL98
(a novel antiviral target) and subsequent virtual screening of its active site; and iii)
explicit treatment of interfacial waters during protein-protein docking process using
HINT-based computational tools.
SphK2 is a key regulator of the sphingosine-rheostat, and its upregulation
/overexpression has been associated with cancer development. We report structural
modeling studies of a novel TZD-analog that selectively inhibits SphK2, in a HINT
analysis that identifies the key structural features of ligand and protein binding site
responsible for isoform selectivity.
The second aim was to build a three-dimensional structure of a novel HCMV
target – AN UL98, to identify its catalytically important residues. HINT analysis of the
interaction of 5’ DNA end at its active site is reported. A parallel aim to perform in silico
screening with a site-based pharmacophore model, identified several novel hits with
potentially desirable chemical features for interaction with UL98 AN.
The majority of current protein-protein docking algorithms fail to account for water
molecules involved in bridging interactions between partners, mediating and stabilizing
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their association. HINT is capable of reproducing the physical and chemical properties
of such waters, while accounting for their energetic stabilizing contributions. We have
designed a solvated protein-protein docking protocol that explicitly models the Relevant
bridging waters, and demonstrate that more accurate results are obtained when water is
not ignored.

CHAPTER 1
INTRODUCTION
	
  
	
  
	
  
1.1 The Hydrophobic Effect
In chemistry, hydrophobicity (coming from Greek words hydro, meaning water,
and phobos, meaning fear) is the physical property/tendency of a non-polar molecule to
form aggregates in order to reduce their surface area exposed to a surrounding polar
environment. This hydrophobic effect affects a number of diverse systems – from
something as simple as immiscibility of oil in water to more complex phenomenon at the
molecular level like protein folding and ligand binding.1 Decades of research into
understanding the biomolecular environment has established the fact that four major
types of non-covalent interactions – hydrogen bonds, ionic interactions, Van der Waals
interactions and hydrophobic interactions, govern nearly all processes at the molecular
level, which is at the core of biological action.
While a “bond” is definitely not created, Kauzmann coined the term –
hydrophobic bond, to describe the adhesion tendency of non-polar molecules within an
aqueous solution.2 Through the mid-twentieth century, the concept of a bond between
two non-polar molecules was widely accepted, since this attractive force was unusually
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strong. However, with a better understanding of the physical properties of dilute
solutions of hydrophobic molecules in water, it was recognized that this attraction is a
more complex phenomenon involving the configurational rearrangement of polar water
molecules as the two hydrophobic species come together.3 The association/aggregation
of non-polar molecules due to the hydrophobic effect is energetically favorable due to
the increase in entropy associated with the release/scattering of ordered water
molecules surrounding them. The manifestations of the hydrophobic effect have been
well reviewed in the literature.1,4,5
A large number of biological processes like protein folding; absorption,
distribution, metabolism, and excretion of biological molecules; molecular recognition;
protein-ligand interactions; protein-protein interactions; and more are governed by
hydrophobicity. The hydrophobic effect plays a central role in guiding protein structure.
Water-soluble proteins organize themselves such that amino acids with hydrophobic
side-chains are retained within the core and buried from water, while amino acids with
charged and polar side-chains are located on the solvent exposed surface, where they
are capable of interacting with the surrounding water molecules. The hydrophobic effect
makes a significantly large contribution towards the stability of globular proteins, and
together with hydrogen bonding interactions within the core, drives the protein folding
process.6 The basic physical principles of molecular recognition are governed by
thermodynamics, especially the Gibbs free energy (Δ𝐺), which is given by –
𝚫𝑮 =   𝚫𝑯 − 𝑻𝚫𝑺
described by the sum of changes in enthalpy (ΔH) and entropy (–TΔS) of the system.
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(1)

The hydrophobic effect largely contributes towards the entropic term. Protein-ligand or
protein-protein binding events involve bringing two molecules together, mainly via
formation of electrostatic interactions like hydrogen bonds or hydrogen-bonding
networks formed through water molecules. Those water molecules that are unable to
locate within the binding interface are displaced into the bulk solvent, increasing entropy
of the system.
For medicinal chemists engaged in drug discovery, the atomistic level
understanding of how biomolecules associate (both intra- or intermolecular) and the
precise chemical and physical features responsible for mediating them is of utmost
importance. Structure-based drug design efforts rely on the knowledge of 3D structure
of therapeutically relevant biomacromolecules and complexes. On the other hand,
ligand-based drug design efforts rely only on the knowledge of physicochemical
properties of small-molecules/ligands that bind to these biological targets of interest.
These efforts aim to identify and optimize the biomolecular interactions, in search of
novel, more potent drugs. The following section will review the different types of
molecular interactions present in a single protein-ligand complex, from the vantage point
of a medicinal chemist.

1.2 Molecular Interactions
A comprehensive review on the specific types of intermolecular interactions
between ligands and their host molecules has been described elsewhere,7 and should
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be referred to for intricate details. Here, we will focus on some of the more frequently
observed interactions observed in protein-ligand crystal structures.
One of the most important specific molecular interactions in ligand binding,
biomacromolecular associations and related phenomenon is hydrogen bonding. Its
structural and functional role in processes like protein secondary structure stabilization,
protein folding, molecular recognition, enzymatic reactions, has been well documented.8
It is a well-accepted fact that hydrogen bonds are primarily electrostatic and highly
directional in nature.9,10 The prevalence of different types of hydrogen bonding
interactions within protein structures and in their complexes with ligands, like
interactions between NH and carbonyl groups; between OH and carbonyl, ether and
ester groups; and those with aromatic heterocycles; has been studied from crystal
structure databases.7,11-13 The traditional distance preference, the ‘van der Waals
distance cutoff’, for identifying a hydrogen bond is too limiting and X–HA interactions
with median distances between the proton and acceptor atom up to 3.0 Å have been
observed.14 Also, there are pronounced angular preferences for hydrogen bonds – with
linear interactions (angles > 150°) preferred, although the location of electron density,
molecular dipole and other neighboring intermolecular forces may influence the
geometry to deviate.7 While extremely important in conveying specificity to a recognition
process, the contribution of hydrogen bonding towards net binding free energy gain is
minimal in most cases as desolvation of the donor and acceptor atoms must occur for
the interaction to form, and as a result, the effects of hydration and hydrogen bond
formation counterbalance each other.15 This also holds true for salt bridges, where the
hydrogen bond distances are comparatively shorter and the interaction stronger.16 Since
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hydrogen bonds differ significantly in their intrinsic strengths, Laurence, C. et al. have
recently introduced the pKBHX scale, the hydrogen-bond basicity scale, to determine the
relative strength of a hydrogen-bond acceptor.17 This scale is created by measuring the
equilibrium constant of the reaction of formation of hydrogen bond for a series of bases
under the same conditions. It provides medicinal chemists a tool to probe the strength of
a hydrogen bonding interaction systematically in an attempt to design more potent and
selective analogues.18,19 Other aspects of hydrogen bonds often observed in intra- and
intermolecular interactions like cooperative hydrogen bonding, referring to additional
hydrogen

bonds

in

the

vicinity

that

mutually

strengthen

each

other;20

multicentered/branched hydrogen bonds, referring to the stabilization of a hydrogen
bond by additional partners to satisfy the hydrogen bonding potential;21 and neighboring
acceptor and donor groups that might weaken a hydrogen bond;22 also require attention
of the designer of drugs.
Numerous instances of weaker hydrogen bonds, involving non-classical donors
and acceptors, have been observed in proteins.21 The π-electron cloud of an aromatic
ring can act as hydrogen bond acceptor to classical amide NH and hydroxyl OH donors,
as well as hydrogens of aromatic XCH units polarized by neighboring heteroatoms (X =
O, N).23 Other frequently observed weak hydrogen bonds in crystal structures are
CFHN and CFHO interactions, the Cα-HO=C interactions, the Cα-HF
interactions, a SHπ-system interaction, etc.24-27 A different kind of hydrogen bond-like
interaction is the cation-π interaction. Cations, from small ions like Li+ to complex
groups like guanidinuim and ammonium, are strongly attracted to π electrons of
aromatic side-chains of Phe, Tyr, and Trp. Stacking interactions of the guanidino-group
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of arginine with the aromatic rings of nucleic acid are conserved in some protein-nucleic
acid complexes. Not just cations, but methyl groups bound to an electronegative atom
(like alkylammonium group) are also capable of interacting with the π face of aromatic
rings.28,29
Another type of non-covalent interaction observed between protein and ligand is
the halogen bond. Halogen atoms of small-molecule ligands, when bound to aryl or
electron withdrawing alkyl groups, show attraction towards carbonyl groups and other
classical hydrogen-bond acceptors found in proteins, resulting in a C–XB type of
interaction (X – halogen atom; B – electronegative acceptor atom).30 The strength of a
halogen bond is highly dependent on a number of things – the size of the halogen atom
(the larger the halogen atom, the stronger the interaction), the electronegativity of the
carbon substituent in the C–X partner (the higher the electronegativity, the stronger the
interaction), and the electron density of the binding partner.31,32 Similar to the cation–π
interactions, a weak favorable interaction has also been observed between aromatic
rings and halogen substituents.33 Various groups have performed detailed analyses of
different interactions involving halogen atoms, with results emphasizing the fact that
halogens should not be viewed as only lipophilic groups, but can be utilized to form
electrostatic interactions within the protein binding site under appropriate conditions.
One of the most important non-covalent interactions prevalent in almost all
protein-ligand/protein-protein complexes is the hydrophobic interaction. The formation of
strong interactions between non-polar ligands and a lipophilic protein pocket, formed by
side chains of non-polar amino acids like leucine and phenylalanine, can be attributed to
the hydrophobic effect. Similar to aggregation/micelle formation, a non-polar ligand
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prefers to bind to a hydrophobic protein pocket resulting in decreased surface area
exposed to waters, for both the ligand and the protein, and a subsequent gain in
entropy, thus making the entire process energetically favorable. Hydrophobic
interactions involving aryl-aryl/aryl-alkyl groups in host and guest molecules are
facilitated by the electronic properties of the interacting aromatic rings. In case of arylaryl interactions, the aromatic side chains of protein residues interact with aryl rings of
the ligand in a parallel-displaced stacking arrangement, maximizing overlap of the πsystems. The stacking arrangement between electron-rich hosts (due to electrondonating substituents) and complementary electron-deficient guests (due to electronwithdrawing substituents) affords charge transfer, thereby strengthening the interaction.
In case of heterocyclic aromatic rings, the orientation of the interaction is controlled by
the complementary alignment of partial charges on atoms and molecular dipoles.34 In
contrast to aryl-aryl interactions, the interaction between an alkyl group and an aromatic
ring is more biased towards an edge-to-face geometry. The interaction energy of this
type of interaction can be increased with increasing the acidity of the interacting CH unit
of the alkyl partner.35 Significant binding energy gains can be achieved by promoting
intermolecular hydrophobic interactions, as evident from various studies showing
correlation between binding affinity and the amount of hydrophobic surface buried upon
ligand binding.36
Knowledge of the various interactions discussed above leads to better
understanding of protein-ligand complexes, and draws the attention of a medicinal
chemist / drug designer to the fact that there are multiple interactions involved in the
binding process and any particular interaction must not be overemphasized.
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1.3 Interfacial Structural Waters
Interfacial waters are not just “spectators” to ligand-binding or protein-protein
association process; every such event involves displacement of water molecules from
the binding site. The majority of biomolecular interactions occur in aqueous medium –
each interacting partner is surrounded by water molecules, and the changes in the
water structure upon their association contributes significantly towards the entropic
component of the Gibbs free energy. Also, due to its high polarity, the presence of water
molecules significantly changes the electrostatic interactions at the binding interface,
and thereby contributes towards the enthalpic component too. Although having just
three atoms, a single water molecule can engage in four hydrogen bonds (two as donor
and two as acceptor). This enables water to mediate binding between protein and its
ligand (both small-molecules and other proteins) via a hydrogen-bonding network.37 In
fact, analysis of thousands of protein-ligand crystal structures has revealed the
presence of at least one water-mediated bridging interaction in each binding site.38
Detailed analysis of the interface of protein complexes has shown that 40.1% of
interfacial residues interact through water.39 These studies highlight the importance of
including the contribution of water molecules in rational ligand design.
Several studies have shown the utilization of structural waters at binding sites in
ligand optimization efforts – either promoting water mediated interaction or designing an
analogue that displaces it. One such example that illustrates the importance of water
molecules at active site and its exploitation in inhibitor design is that of HIV-1 protease.
The unliganded crystal structure of HIV-1 protease40 shows the presence of catalytically
important water Wat300, coordinated to an Asp residue in its active site. This water
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molecule is consistently displaced when a ligand binds, disrupting the enzyme’s
catalytic activity. Another water molecule in its active site, Wat301, that forms hydrogen
bonds with backbone amides of the two symmetry related Ile residues, is detected in
crystal structures of the protease in its free form and in complexes with different
ligands.41 The conservation of this water molecule initially led to efforts directed at
designing ligands that provide hydrogen bond acceptors to the protons of Wat301,
resulting in potent inhibitors. However, ligands designed to displace this water proved to
be even more tight binders, owing to the gain in entropy achieved by releasing that
water into bulk solvent.42,43 In another study, a nitrile substitution in the quinalozine and
benztriazine inhibitors of scytalone dehydrogenase with an aim to displace water
molecule from the active site, again resulted in more potent inhibitors.44 Similarly,
introduction of a nitrile group into quinazoline-based inhibitors of EGFR kinase led to
more potent inhibitors, with the cyano-group interacting with the active site Thr in a
similar manner to a water molecule.45 Such studies and many more, have indicated that
water molecules can be viewed as an extension of or addition to protein structural
features, and they should be treated explicitly to assist rational ligand design and also
guide modeling techniques like ligand docking / protein-protein docking.

1.4 Free Energy and Binding Affinity
The previous sections shed light on the different molecular interactions prevalent
in protein-ligand complexes – direct molecular interactions, as well as the influence of
water molecules. Drug discovery efforts largely rely on the accurate assessment of all
	
  

9

different effects that might influence the binding of small-molecule ligands with the
target protein. The quantitative knowledge of the forces that guide the binding process
thus becomes very important. The binding affinity of two molecules to form a complex
must be rationalized and understood in terms of Gibb’s Free Energy (Δ𝐺).
A non-covalent, reversible association of protein (𝑃) and ligand (𝐿) to form a
protein-ligand complex ( 𝑃′𝐿′ ) usually occurs in an aqueous solution, and can be
represented by the following equation –
𝑷𝒂𝒒. +    𝑳𝒂𝒒.    ⇄ 𝑷′𝑳′𝒂𝒒.

(2)

Under thermodynamic equilibrium conditions, the association constant 𝐾! (or the
dissociation constant 𝐾! ) is given by the following equation –
𝑲𝒂 =    𝑲!𝟏
𝒅 =   

𝑷′𝑳′
𝑷 𝑳

(3)

The experimentally determined dissociation constant 𝐾! (in case of enzyme
inhibition, the inhibition constant 𝐾! ) can be related to the standard Gibb’s free energy
change of the dissociation (∆! 𝐺 ° ) of 𝑃! 𝐿! as –
∆𝒅 𝑮° =   𝑹𝑻𝒍𝒏𝑲𝒅

(4)

where 𝑅 is the gas constant and 𝑇 is the absolute temperature (𝑇 = 298 K).
The more negative the value of ∆𝐺 ° , the smaller the dissociation constant 𝐾! , and
the stronger the binding. This relationship shows that the affinity of a molecule towards
a target protein can be determined by calculating the associated changes in the
thermodynamic parameters of the system – the changes in standard enthalpy and
standard entropy upon complex formation.
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It is generally accepted that protein-ligand binding events are determined by not
only electrostatic interactions like hydrogen bonds, salt bridges, dipole-dipole
interactions,

interactions

with

metal

ions,

but

also

contributions

from

solvation/desolvation processes and spatial complementarity in van der Waals
interactions.46 The binding process is a complex phenomenon, and the enthalpy and
entropy changes associated with direct interaction between protein and ligands are
often not sufficient to describe the free energy change of the entire system. In the
biological environment, both interacting partners are solvated before binding. The first
event in the binding process is the desolvation of the ligand molecule and the proteinbinding site, which contributes to free energy changes. Next is the conformational
change in the protein side chains and ligand molecule, which also results in a change of
entropy. This is followed by the energy gain attained from the molecular interactions
forming between the interacting partners. Finally, if solvent accessible, the proteinligand binding site is resolvated; with a favorable free energy if water molecules are set
around polar/ionic groups and an unfavorable free energy if they are largely around
hydrophobic groups. The total free energy change of the system (∆𝐺!"#$ )  arises from
contributions from each step of the binding process, and should be taken into account in
calculations. The master equation can be written as –
∆𝑮𝒃𝒊𝒏𝒅 =    ∆𝑮𝒔𝒐𝒍𝒗𝒆𝒏𝒕 +    ∆𝑮𝒄𝒐𝒏𝒇 +    ∆𝑮𝒊𝒏𝒕 +    ∆𝑮𝒎𝒐𝒕𝒊𝒐𝒏

(5)

where, ∆𝐺!"#$%&' is the hydration free energy, ∆𝐺!"#$ free energy contribution due to
conformational changes in the protein and ligand, ∆𝐺!"# is the free energy change due
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to specific interaction between protein and ligand, and ∆𝐺!"#$"% is the free energy
change due to “motion” in protein and ligand once they are proximal.47
1.4.1 Experimental measurement of binding free energy
Experimental determination of binding affinities can be achieved by indirect
methods like binding assays. For enzyme reactions, the influence of ligand binding on
enzyme kinetics results in a change in some physical property (like absorption,
fluorescence, fluorescence polarization), which is subsequently measured. For receptor
binding studies, a suitably labeled ligand is used. In both cases, the measured property
is used to indirectly determine the binding constant and the standard free energy
change (∆𝐺 ° ). Recently, physicochemical techniques like Surface Plasmon Resonance
spectroscopy,48 NMR spectroscopy,49 Mass spectroscopy,50 and also Atomic-Force
microscopy51 have been used for indirect measurements of binding constants. A more
direct measurement of binding affinities can be accomplished through microcalorimetric
measurements, such as using Isothermal Titration Calorimetry (ITC). ITC is a highly
versatile technique that allows determination of the complete thermodynamic profile
(binding constant K, stoichiometry n, enthalpy change ΔH, entropy change ΔS) of a
protein-ligand interaction from a single label-free experiment.52
For

medicinal

chemists,

the

affinity

of

small-molecule

ligand

for

a

macromolecular protein is of utmost importance as it serves as a benchmark criterion to
define its biological activity. Lead discovery and optimization process is aimed at
attaining better binding affinities by improving the intermolecular interactions, thereby
leading to more potent drug candidates. However, synthesizing every potential
analogue of a prototype candidate molecule and its subsequent experimental binding
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affinity determinations are impractical, as they demand substantial resources. A more
rapid, cost-efficient, approach would be to computationally predict the binding affinities
of these analogues, which in turn will aid in selection of lead compounds or drug
candidates with more favorable chemical characteristics.
1.4.2 Theoretical calculation of binding free energy
Various theoretical approaches for prediction of binding affinities have been well
documented in literature.15,46,53 Classical molecular mechanics forcefield-based scoring
functions quantify protein-ligand interaction by focusing mostly on the steric and
electrostatic

forces

involved.

The

solvation/desolvation

effects

and

entropic

contributions to binding events are often poorly described, and in some cases ignored.54
Empirical scoring functions, on the other hand, are designed to approximate the binding
affinities based on the individual interactions within a protein-ligand complex. The
individual interaction terms accounting for favorable enthalpic contributions arising from
electrostatic and hydrophobic contacts, as well as unfavorable entropic contributions
arising from immobilization of rotatable bonds upon complex formation, may be
implemented in the scoring function. The dependence of these methods on the quality
of experimental data sets used to perform regression analysis and fitting, is a major
reason for lack of accuracy in some approaches.54 A third category of scoring functions
– knowledge-based scoring functions – are based on simple atomic interaction-pair
potentials derived from the observed frequencies of atom-pairing within crystal
structures of known protein-ligand complexes.55 Similar to empirical methods, a
knowledge-based scoring function attempts to implicitly account for enthalpic and
entropic contributions to binding. Despite the increasing number of scoring functions
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being developed for accurate predictions of binding affinities, no general-purpose
function is available. Most make various assumptions and simplifications for faster
calculations, and do not completely describe every physical phenomenon involved in
molecular recognition.54 Indeed, the binding phenomenon itself is complex, with many
moving parts, and only partially understood.

1.5 The HINT (Hydropathic INTeraction) Model56-58
Kellogg and Abraham designed a novel empirical force field named HINT
(Hydropathic INTeraction) for calculating intermolecular interactions and free energies,
based on experimentally determined partition coefficients 𝐿𝑜𝑔  𝑃!/! .
The octanol/water partition coefficient (𝐿𝑜𝑔  𝑃!/! ) of a molecule A is the ratio of its
equilibrium concentration in a mixture of two immiscible solvents –
𝑳𝒐𝒈  𝑷𝒐/𝒘 = 𝑳𝒐𝒈  

𝑨 𝒐𝒄𝒕𝒂𝒏𝒐𝒍
𝑨 𝒘𝒂𝒕𝒆𝒓

(6)

1-octanol is a hydrophobic solvent that serves as a model environment to represent the
biological phospholipid membrane. Thus, the distribution of a compound between water
and 1-octanol provides accurate approximation of its partitioning between the cytosol
and lipid membranes of living systems. The solvent partitioning phenomenon, much like
the molecular recognition process, is governed by the same set of forces – the polar
and electrostatic interactions guide the polar part of a molecule towards hydrophilic
solvent (water) and the hydrophobic interactions guide the hydrophobic part of the
molecule towards hydrophobic solvent (1-octanol). As a result, 𝐿𝑜𝑔  𝑃!/! values implicitly
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include the effects of entropy and solvation, along with other non-covalent interactions
like hydrogen bonding, Coulombic, acid-base, hydrophobic interactions, etc. The HINT
model uses the 𝐿𝑜𝑔  𝑃!/! values for classification and quantitative scoring of molecular
interactions, thereby incorporating both polar and hydrophobic complementarity,
collectively referred to as hydropathy, between biomolecules. The quantitative solvent
partitioning measurement (using experiments like the shake-flask method) can be
viewed as free energy experiments and encode thermodynamic information, such that
the standard free energy change of the solute transfer process (∆𝐺°) can be related to
its equilibrium constant (𝐿𝑜𝑔  𝑃!/! ) using the following equation –
𝑳𝒐𝒈  𝑷𝒐/𝒘 =    −  ∆𝑮° 𝟐. 𝟑𝟎𝟑  𝑹𝑻

(6)

where R is the gas constant and T is the absolute temperature. Thus:
𝑳𝒐𝒈  𝑷𝒐/𝒘 =   𝒌  ∆𝑮°

(7)

where 𝑘 = –0.733 kcal/mol at 298K.
This relationship shows that HINT force field, which is based on 𝐿𝑜𝑔  𝑃!/! , can be used
to estimate the free energy of a binding process, and thereby predict the binding
affinities of ligands.
The HINT molecular interaction model calculates free energy scores for the
hydropathic interactions within/between biomolecules by quantifying each atom-atom
pair interaction using the following equation –
𝒃𝒊𝒋 =    𝒂𝒊   𝑺𝒊   𝒂𝒋   𝑺𝒋   𝑻𝒊𝒋   𝑹𝒊𝒋 +    𝒓𝒊𝒋
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(8)

where 𝑏!" is the hydropathic interaction score between atoms 𝑖 and 𝑗 . 𝑎 is the
hydrophobic atom constant, 𝑆 is the solvent accessible surface area (calculated using a
H2O probe), 𝑇!" is a logic function assuming +1 or –1 value depending on the character
of the interacting polar atoms, and the distance dependent functions 𝑅!"   and 𝑟!"   are
simple exponential function e-r and an implementation of the Lennard-Jones potential
function, respectively. The total score of the system is then calculated by taking a
double sum over every atom-atom pair –
𝑯𝑰𝑵𝑻𝒕𝒐𝒕𝒂𝒍 =   𝚺  𝚺  𝒃𝒊𝒋

(9)

The HINT force field scores favorable interactions with 𝑏!" > 0 , and unfavorable
interactions with 𝑏!" < 0 . The value of logic function 𝑇!" depends on the type of
interacting atoms. A favorable hydrophobic-hydrophobic interaction gets a 𝑇!" =    +1
value; an unfavorable hydrophobic-polar interaction gets a 𝑇!" =    −1 value; for a polarpolar interaction, 𝑇!" =    +1 if the interacting atoms are an acid and a base, whereas
𝑇!" =    −1 for an unfavorable acid-acid/base-base type interaction. Table 1.1 shows the
𝑇!" interaction matrix.
The hydrophobic atom constant, 𝑎, is calculated by an adaptation of a partitioning
algorithm CLOP of Hansch and Leo,59 which calculates the total solvation partition
constant for a molecule by summation of fragment constants into a single value. HINT,
on the other hand, uses a slightly different approach – it distributes and assigns
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Table 1.1 – 𝑇!" interaction matrix57
Atom Type
[atom constant]
H (apolar)
[a>0]
H (polar)
[a>0]
C (apolar)
[a>0]
Polar (N, O, etc)
[ a < 0]

H (apolar)
[a>0]

H (polar)
[a>0]

C (apolar)
[a>0]

Polar (N, O, etc)
[ a < 0]

+1

-1

+1

-1

-1

-1

-1

+1

+1

-1

+1

-1

-1

+1

-1

-1

Colors code: Green – favorable hydrophobic-hydrophobic; Red – unfavorable
hydrophobic-polar; Blue – favorable acid-base or hydrogen bond; Yellow – unfavorable
acid-acid; Orange – generally unfavorable base-base, but may depend on charge.
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hydrophobic atom constants and factors to each atom in the molecule. HINT uses
values from a functional group primitive dataset of small molecules and biomacromolecules, with re-parameterized force field atom types; modified factors for
bond, branching, ring and chain factors; and polar proximity factors. The modifications
represent real biophysical phenomena related to the molecular structure and properties.
The hydrophobic atom constant for every atom of the molecule is calculated by
modifying the factors based on the atom’s structural connectivity and proximity to other
atoms. The 𝐿𝑜𝑔  𝑃 of the molecule can be considered as the sum of individual
hydrophobic atom constants (𝑎! ) –
𝑳𝒐𝒈  𝑷 =   𝚺  𝒂𝒊

(10)

Most importantly, the hydrophobic atom constant is a thermodynamic parameter whose
sign and magnitude reveals the potential type and strength of the interaction that the
atom may engage in.
One of the most significant aspects of the HINT model is that it is empirical in
nature and approximates all non-covalent interactions in the biological environment,
including hydrogen bonding, electrostatic and hydrophobic interactions. Moreover,
entropy and solvation/desolvation effects are also implicitly encoded in the 𝐿𝑜𝑔  𝑃 data.
The hydrophobic atom constants (𝑎! ) are parameters directly derived from the free
energy of atom transfer between two solvents – which means that these solvents serve
as model environments for hydrophobic and polar regions of biomolecules and the free
energy of atom transfer between hydrophobic and polar regions of biomolecules is the
same as that between 1-octanol and water. That is, the 𝑎! values of each atom indicate
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how it will interact with other atoms in a biological micro-environment, much as how it
interacts with solvent molecules/atoms. For example, for atoms 𝑖 and 𝑗, positive values
of 𝑎! and 𝑎! imply that they are hydrophobic and the HINT algorithm would score the 𝑖/𝑗
interaction favorably (𝑏!" > 0). If 𝑎! and 𝑎! are both negative, and one is a Lewis acid
while the other is a Lewis base, the HINT algorithm would score the 𝑖/𝑗 interaction
favorably also ( 𝑏!" > 0 ). However, if 𝑎! is positive and 𝑎! is negative, the 𝑖/𝑗
hydrophobic-polar type interaction would be scored unfavorably (𝑏!" < 0). Table 1.2
shows the matrix of atom-atom interaction types characterized and scored by the HINT
algorithm.

The HINT force field and its free energy scoring form the basis for quantitative
assessment of molecular interactions, which as we have discussed before, has a direct
consequence in drug design. Within a homogeneous biological set (i.e., within families
of different ligands binding to the same protein site), HINT scores can be easily
correlated to the binding free energy associated with protein-ligand complex formation.
Kellogg et al. have shown that total HINT interaction scores correlate with the ∆𝐺!"#$"#%
(Figure 1.1) for a diverse set of 76 protein-ligand complexes at resolution better than 3.2
Å, with a standard error of ± 2.33 kcal mol-1 using the equation –
∆𝑮𝒃𝒊𝒏𝒅𝒊𝒏𝒈 =    −𝟎. 𝟎𝟎𝟏𝟗  𝑯𝒕𝒐𝒕𝒂𝒍 − 𝟑. 𝟗𝟐𝟕

(11)

A better correlation was achieved within a subset of 56 complexes structurally
determined at a resolution better than 2.5 Å (r = 0.85, SE = ± 1.8 kcal mol-1).60
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Table 1.2 – Types of atom-atom interactions characterized and scored by HINT force
fields57
Polar – Lewis Acid Polar – Lewis Base
(H-bond donor)
(H-bond acceptor)
Hydrophobic – Polar Hydrophobic – Polar
(desolvation energy) (desolvation energy)

Hydrophobic
Hydrophobic

Hydrophobic
interaction

Polar – Lewis Acid
(H-bond donor)

Hydrophobic – Polar
Coulombic repulsion
(desolvation energy)

Polar – Lewis Base
(H-bond acceptor)

Hydrophobic – Polar
(desolvation energy)
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Acid – Base
(Hydrogen bond)

Acid – Base
(Hydrogen bond)
Coulombic repulsion

Figure 1.1 Correlation between calculated HINT scores and measured free energy of
binding for 76 diverse protein-ligand complexes (crystallographic resolution better than
3.2 Å). Reprint from ref 60.
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The capability of predicting the free energy of binding, especially since it has
terms for hydrophobic interactions, in addition to the electrostatic, van der Waals and
desolvation, makes HINT a suitable tool for scoring predicted binding modes of ligands
in a docking experiment, in order to identify the best conformation. Several studies have
successfully used HINT to distinguish active molecules from inactive ones.61-64
One of the earliest applications of HINT was incorporation of the HINT
hydropathic fields into 3D-QSAR program CoMFA,65 which originally had just two fields,
steric and electrostatic. The introduction of hydropathic field enables full description of
binding events and aids in designing new molecules based on such QSAR studies,
especially in cases where ligands and/or active sites are predominantly non-polar in
nature. Several studies based on the HINT–CoMFA are reported in the literature.66-69
An important consideration for reliable modeling results is the exact designation
of protonation state of ionizable groups of both protein side chains and ligands, which
can have significant influence on binding affinities. The hydropathic analysis can be
performed using the HINT force field to assign the location of hydrogens on functional
groups within the binding pocket, using an extension of the HINT model known as
Computational Titration.70 Multiple potential ionization states for protein and ligand are
enumerated and analyzed by the HINT model, with the best scoring complex
representing the optimum state of binding and its corresponding protonation ensemble.
As discussed before, interfacial water molecules mediate and stabilize the
molecular recognition phenomenon – either directly via hydrogen bonding network or
indirectly via solvation/desolvation processes. The contribution of bulk solvent towards
the hydrophobic effect (the desolvation energy, entropic in nature) is implicitly encoded
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within the 𝐿𝑜𝑔  𝑃!/! data. However, the solvent molecules forming bridging interactions
between ligand and protein must be explicitly accounted for. The HINT force field can
calculate the global interaction score for a water-mediated protein-ligand interaction
(𝐻𝑆!"!#$ ) by incorporating the contribution made by water –
𝑯𝑺𝒕𝒐𝒕𝒂𝒍 =    𝑯𝑺𝒑𝒓𝒐𝒕!𝒍𝒊𝒈 +    𝑯𝑺𝒍𝒊𝒈!𝒘𝒂𝒕𝒆𝒓 +    𝑯𝑺𝒑𝒓𝒐𝒕!𝒘𝒂𝒕𝒆𝒓

(12)

where, 𝐻𝑆!"#$!!"# is the interaction score between protein and ligand; 𝐻𝑆!"#!!"#$% is the
interaction score between ligand atoms and water molecules; and 𝐻𝑆!"#$!!"#$% is the
interaction score between protein atoms and water molecules (at the binding site),
which can be ignored if those waters are preexisting, i.e., part of the protein. This global
interaction score was shown to correlate with experimentally determined binding
constants better than the scores when waters were ignored (SE = ± 0.98 kcal mol-1).71
The capabilities of HINT force field, and tools based on it, make it a highly
versatile tool with numerous applications in drug designing. The HINT toolkit, a set of
linkable subroutines that access HINT energy scoring functions and HINT 3D grid map
objects, is made available to the scientific community and can be incorporated into
programs for computer aided drug discovery.72

1.6 Research Plan
In addition to quantitatively scoring molecular interactions, the HINT force field
can – (i) create hydropathic fields for ligands within a protein environment, (ii) rationally
evaluate the correct ionization states of functional groups within a protein binding site,
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(iii) incorporate energetic contribution of interfacial waters, and (iv) enhance
crystallographic data by optimizing the protein residue interaction environment. The
overall aim of this research work was to utilize the HINT force field and HINT-based
computational tools in various aspects of molecular modeling. Our overarching goal is to
apply this atomistic-level simulation technology to important biological proteins in order
to gain structural insights into their mechanism of action that can be exploited for
designing compounds intended to inhibit them.
Sphingosine Kinase (SphK) is a key regulator of the sphingosine rheostat, which
maintains optimum levels of a lipid metabolite sphingosine-1-phosphate (an antiapoptotic agent).73 Overexpression and/or upregulation of SphK have been associated
with various aspects of cancer development.74-76 Biological characterization of a
thiazolidine-2,4-dione (TZD) analogue identified it as an isoform-selective SphK2
inhibitor.77 We asked ourselves if the key structural features of the ligand and the
protein binding site, which makes it isoform selective, could be identified using the HINT
force field. This is important to optimize the lead compound for future drug development.
In Chapter 2, we will discuss the protein structure building process for the two human
isoforms of SphK (SphK1 and SphK2). This was followed by molecular docking of the
ligand to its putative binding site on the kinases. Using molecular docking and HINT free
energy scoring to identify the probable native-like conformation of ligand within the
binding pocket, we propose a binding mode for the TZD-analogue showing a preference
for SphK2.
Human cytomegalovirus (HCMV) is a human pathogen responsible for diseases
in immune-compromised and HIV patients, and severe birth defects when acquired
	
  

24

during pregnancy.78 The HCMV Alkaline Nuclease (AN) UL98, vital for viral replication,
represents a novel target for development of antivirals.79 In the absence of a
crystallographic structure, we wanted to see if molecular modeling techniques could be
used to build a structural model to identify UL98’s catalytically important residues. In
Chapter 3, we will discuss the homology-based structural modeling of UL98 AN. The
computational model has been experimentally validated, and subsequently used to
perform a structure-based virtual screening with an aim of identifying novel agents
capable of inhibiting UL98.
Finally, in Chapter 4 we will discuss the utility of HINT based tools in designing a
solvated protein-protein docking protocol. With increasing interest in targeting proteinprotein associations to interrupt biochemical pathways, and relatively few crystal
structures of protein-protein complexes available, it becomes very important to have
computational tools for accurate prediction of these biomacromolecular associations.
Various HINT-based studies have shown the importance of interfacial waters in
mediating and stabilizing protein-protein complexes.71,80-82 The majority of current
docking algorithms include the effects of solvent by introducing desolvation energy
terms in their scoring functions; however, they fail to account for the water molecules
involved in bridging interactions. With HINT-based tools that can explicitly account for
interfacial waters at our disposal, we wanted to check the influence of accounting for
their energetic contributions on the outcome of docking predictions. Using these tools,
we have designed a solvated protein-protein docking protocol that explicitly models the
Relevant bridging interfacial waters, and demonstrate that more accurate results are
obtained.
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CHAPTER 2
THIAZOLIDINE-2,4-DIONE (TZD) ANALOGUE K145 – SELECTIVE SPHK2 INHIBITOR

2.1 Introduction

2.1.1 Sphingolipids – Structure and Function
Sphingolipids and glycosphingolipids are complex lipids containing the sphingoid
backbone, i.e., a long-chain aliphatic C18 – C20 backbone linked to a fatty acid via its
acyl group, and attached to a charged head group such as ethanolamine, serine or
choline through an O-linkage. Sphingosine and dihydrosphingosine, which are just longchain sphingoid bases are the simplest possible functional sphingolipids. Ceramide, a
complex sphingolipid, has a fatty acid linked to the base by an amide bond. More
complex sphingolipids are formed by addition of head groups to ceramide, such as
sphingomyelins and cerebrosides that contain phosphocholine/phosphoethanolamine
and glucose/galactose attached to the 1-hydroxy group of ceramide by an ester linkage
and β-glycosidic linkage, respectively. Figure 2.1 shows the general structures of some
sphingolipids.
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Sphingolipids play very important structural and functional roles in the plasma
membranes of eukaryotic cells.1 Over the last decade, significant studies have also
shown their importance in non-structural roles. Sphingolipids have been demonstrated
to be an important signaling mediator for vital cellular and physiological processes such
as cell motility, invasion, proliferation, angiogenesis and apoptosis.2-6 Sphingolipids and
their metabolites contribute to various cellular signaling pathways either by directly
interacting with GPCRs or by acting as intracellular second messengers capable of
interacting with a plethora of targets.7 Plasma membranes of many cell types contain
lipid rafts, which are involved in various cellular processes like signal transduction,
membrane trafficking, cytoskeletal organization, and, inside the nervous system,
implicated in neuronal adhesion, axon guidance and synaptic transmission.8,9 These
lipid

rafts

are

enriched

in

sphingomyelin,

ceramide

and

glycosphingolipids.

Sphingolipids function as secondary messengers by interacting with a number of
proteins and are capable of modifying the activity of various receptors, enzymes and ion
channels, as well as mobilizing intracellular calcium.7 Figure 2.2 shows an overview of
the roles of sphingolipids in cell biology.
The bioactive sphingolipids – sphingosine, sphingosine-1-phosphate and
ceramide – are the central players of sphingolipid-mediated biology. Ceramide and
sphingosine have been associated with growth arrest and apoptosis induced by tumornecrosis factor (TNF) α and Fas ligand.10,11 In contrast, sphingosine-1-phosphate (S1P)
has been demonstrated to play pro-survival roles. S1P induces mitogenesis and acts as
a secondary messenger in cellular proliferation induced by platelet-derived growth factor
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Figure 2.2 – Scheme showing the participation of bioactive sphingolipids – ceramide,
sphingosine and sphingosine-1-phosphate (S1P) in cell biology.
Breakdown of various sphingomyelins by sphingomyelinases (SMases) generates
ceramide. Ceramide can also be synthesized de novo by serine palmitoyl transferase
(SPT) and ceramide synthase. Sphingosine and S1P are generated by ceramidases
(CDases) and sphingosine kinases (SKs). These sphingosine metabolites interact with
specific targets like phosphatases, kinases and GPCRs, which in turn mediate the
effects of these lipids. Adapted from ref 11.
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and serum.12-14 The intracellular levels of these metabolites and their regulatory effects
on the members of MAPKs, rather than their absolute amounts, determine cell fate.10
Regulation of the levels of these sphingolipids, a so-called “sphingolipid rheostat”, is
complex and a number of enzymes have been demonstrated to be important (Figure
2.3).6,11

Figure 2.3 – The Sphingosine Rheostat: Cell fate determinant.

Studies have suggested the possible role of S1P signaling and the Sphingosine
rheostat in carcinogenesis, with sphingolipid metabolism often disregulated.15 Exploiting
the opposing effects of these interconvertible metabolites on cell proliferation for
therapeutic benefit has emerged as an exciting strategy against cancer.

2.1.2 Sphingosine Kinases and Cancer
A key regulator of the sphingosine rheostat is Sphingosine Kinase (SphK), the
enzyme that phosphorylates sphingosine to sphingosine-1-phosphate (S1P), thereby
producing the pro-growth, anti-apoptotic messenger. On the other hand, SphK
decreases the levels of pro-apoptotic sphingosine, and in turn, ceramide. Various
studies have shown that a cell is protected against ceramide-induced apoptosis with
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increased levels of S1P, whereas depleted levels of S1P enhance ceramide-induced
apoptosis.10,16-18 Human sphingosine kinase exists as two isoforms – Sphingosine
kinase 1 (SphK1) and Sphingosine Kinase 2 (SphK2). Although SphK1 and SphK2
share a high degree of homology, they differ significantly in size, tissue distribution and
subcellular localization.19 SphK1 and SphK2 have five conserved domains (C1 – C5)
sharing approximately 50% identity, with SphK2 having about 200 more amino acids
than SphK1. SphK1 mainly resides in the cytosol while SphK2 is present in different
intracellular compartments, including the nucleus, endoplasmic reticulum and
mitochondria.20,21
Over the past few years, evidence has accumulated that suggest associations of
sphingosine kinases with various aspects of cancer development and progression, such
as proliferation, migration, invasion and angiogenesis.22 The very first observation that
proposed the possibility of SphK1 as an oncogene was the transformation of SphK1transfected NIH3T3 fibroblasts to form fibrosarcoma cells, accompanied by increased
S1P formation.23 SphK1 expression has been reported to be upregulated in many
different solid tumor types including breast, lung, kidney, stomach, ovary, uterine and
colon.24-27 Spiegel et al. showed that enforced expression of SphK1 increased S1P
levels and blocked breast adenocarcinoma MCF7 cell death induced by anti-cancer
drugs, sphingosine and TNF-α.28 In another study investigating the significance of
SphK1 in gastric cancer progression, it was observed that SphK1 protein levels were
upregulated in gastric cancer lesions compared to that in adjacent noncancerous
tissues, and patients with higher SphK1 expression have shorter overall survival
times.29 Much less is known about SphK2. Recently, however, it has been shown that
	
  

37

downregulation of SphK2 inhibits the proliferation and migration of tumor cells, such as
glioblastoma and breast cancer cells.30,31 A recent RNA interference study showed that
tumor cell proliferation and migration/invasion were suppressed more by SphK2selective ablation compared to SphK1 ablation.32
There is substantial evidence that S1P, an anti-apoptotic, mitogenic sphingolipid
metabolite generated by the sphingosine kinases, is involved in cancer. A number of
studies have implicated the signaling pathways of S1P in cancer. It regulates processes
such as inflammation, neovascularization, cell growth and survival; all of which are
important for tumor growth/proliferation and motility. For a detailed review, please refer
to Pyne et al.33 Figure 2.4 summarizes the role of S1P in cancer.
As previously mentioned, cell fate is regulated by the sphingosine rheostat and
sphingosine kinases play a major role in maintaining the balance in levels of involved
sphingolipid metabolites. Strategies that shift the ceramide-sphingosine-S1P rheostat
towards the pro-apoptotic/anti-mitogenic ceramide and that inhibit the activity of SphKs
below the optimum level for cancer-cell survival are potential avenues for combating
cancer. The presented evidence of involvement of SphKs in cancer makes them an
ideal target for modulating the sphingolipid-mediated signaling for therapeutic effects.
Although a number of potent and selective SphK1 inhibitors have been developed and
reported,6,34-36 only a few SphK2 inhibitors with moderate potency (Figure 2.5), such as
ABC294640,37 SG-12,38 R-FTY720-OMe39 and trans-12,40 have been reported.
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Figure 2.4 – Summary of role of S1P in cancer.
S1P interacts with a family of GPCRs and regulates processes involved in cancer cell
motility and proliferation. Reprint from ref. 33
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2.1.3 Thiazolidine-2,4-dione Analog K145 – Selective SphK2 Inhibitor41
O
S

O

N

NH2

O

(Z)-3-(2-aminoethyl)-5-(3-(4-butoxyphenyl)propylidene)thiazolidine-2,4-dione
K145
Recently, Dr. Zhang and his research group initiated the development of
thiazolidine-2,4-dione (TZD) analogs as dual-pathway inhibitors of the ERK and Akt
signaling pathways.42,43 The TZD scaffold has emerged as a privileged template in drug
discovery and design because of its frequent appearance in hits in various potential
anticancer agents.44,45 The 3-(2-aminoethyl)-TZD moiety of these inhibitors may be able
to mimic the amino-hydroxyl sphingoid base suggesting the possibility of them being
sphingosine kinase inhibitors (Figure 2.6). Also, it has been shown that an aromatic ring
with an alkyl chain is an important structural feature of SphK inhbitors.35 All these
observations led to the hypothesis that K145, a TZD analog, could be a SphK inhibitor.41
Following the synthesis of K145, biochemical assays as well as in vitro and in
vivo studies were performed in the labs of Dr. Zhang, Dr. Spiegel and Dr. Grant (Virginia
Commomwealth University) to determine its inhibitory activity towards SphKs and its
nature of inhibition, and to examine its apoptotic effects on human leukaemia U937 cells
and demonstrate its in vivo efficacy as a potential lead anticancer agent.
Notably, K145 inhibited the activity of SphK2 in a dose-dependent manner with
an IC50 of 4.40 ± 0.05 µM, while no inhibition of SphK1 at concentrations up to 10 µM
was observed (Figure 2.7A). In contrast, DMS (10 µM) a non-selective SphK inhibitor,
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showed inhibition of both SphK1 and SphK2. This indicated that K145 is a selective
SphK2 inhibitor. Lineweaver-Burk analysis revealed a Ki of 6.4 ± 0.7 µM for SphK2 and
indicated that K145 is a substrate (sphingosine) competitive inhibitor (Figure 2.7B).
Further screening against ceramide kinase, Akt kinase, ERK1/2, PI3K, PKA and other
kinases also demonstrated the relatively high selectivity for SphK2.41
Biological characterization using human leukemia U937 cells demonstrated that
K145 accumulated in U937 cells and inhibited the phosphorylation of FTY720, and also
inhibited the growth of U937 cells, mainly through apoptotic effects. Furthermore, K145
was shown to significantly suppress the growth of U937 tumors in nude mice and
inhibited growth of JC tumor cells in BALB/c mice without apparent toxicity.41
These results strongly indicate that K145 is a selective SphK2 inhibitor
and encourage further optimization of K145 as a novel lead compound to develop more
potent and selective SphK2 inhibitors. This would be of great value as a
pharmacological tool to complement the ongoing molecular and genetic studies, and
help unravel the roles of SphK2 in different pathological and physiological conditions. It
would be useful to have new and adaptable chemical scaffolds available as selective
SphK2 inhibitors that can provide valuable information regarding structural requirements
for designing new SphK2 inhibitors.
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Figure 2.6 – Overlay of K145 (carbon: green) with Sphingosine (carbon: cyan) showing
chemical similarity between the heterocycle of K145 and the amino-hydroxyl sphingoid
head of sphingosine.

Figure 2.7 – Biochemical assays showing K145 as a selective, substrate-competitive
SphK2 inhibitor.
(A) SphK1 and SphK2 activities were measured with 10 µM sphingosine in the absence
or presence of the indicated concentrations of K145 or 10 µM DMS. Data expressed as
percentage SphK activity in the absence of inhibitor. (B) SphK2 activity was measured
with increasing concentrations of sphingosine and indicated concentrations of K145.
Lineweaver-Burk analysis revealed a Vmax of 10820 ± 210 pmol/min per mg of protein,
and a Ki of 6.4 ± 0.7 µM for SphK2.
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2.1.4 Sphingosine Kinase C4 domain – A putative Sphingosine-binding domain
As mentioned before, both sphingosine kinase isoforms have five conserved
domains C1 – C5, sharing about 50% identity (Figure 2.8). The domains, C1 – C3 and
C5, share homology with other kinases like diacylglycerol kinase (DGK) and ceramide
kinase (CerK), with the C2 domain containing the ATP-binding consensus sequence
SGDGX17-21K.46,47
The C4 domain is highly conserved only in SphKs making it the only domain that
might be specific for sphingosine binding. Yokota et al. constructed various mutants of
mouse SphK1, within the C4 domain, in order to identify the residues important for
sphingosine recognition. The negatively charged Asp175, Asp177, Glu179 and Glu181
residues, in the C4 domain of mSphK1, were mutated to Asn and Gln. Also, double
mutants mSphK1aD175N/D177N and mSphK1aD177N/E179Q were prepared. Each mutant was
analyzed for SphK activity using D-erythro-sphingosine and ATP as substrates (Figure
2.9). The results demonstrated that the highly conserved Asp177 is involved in
sphingosine recognition.48
In order to identify the putative Asp residue involved in sphingosine-recognition in
human SphKs, we performed a multiple sequence alignment between mouse SphK1a
and human SphK1 and SphK2. Asp178 in hSphK1 and Asp344 in hSphK2 were
identified as the residues corresponding to the Asp177 of mouse SphK1 in the C4
domain (Figure 2.10).
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Figure 2.8 – Schematic representation of human sphingosine kinase isoforms

Figure 2.9 – Relative sphingosine kinase activities of mouse SphK1a mutants.
(A) Schematic representation of mSphK1 showing the C4 domain and the residues that
were mutated. (B) Relative SphK activities of mSphK1a mutants. The mutants were
analyzed for SphK activity using D-erythro-sphingosine and ATP as substrates.48
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Figure 2.10 – Sequence alignment of the C4 domain of sphingosine kinases.
Asp178 (hSphK1) and Asp344 (hSphK2) were identified as the corresponding residues
important for sphingosine-recognition. Sequence alignment was performed using
Clustal X v2.0,49 image obtained using Jalview,50,51 sequences are colored using the
default Clustal X color scheme (Appendix A.1).
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2.1.5 Specific Aim
To further understand the SphK2 selectivity of K145, we conducted molecular
modeling studies to identify the structural features of K145 that interact with the key
residues of SphK2. Since the biochemical assays showed that K145 is a substrate
(Sphingosine) competitive inhibitor of SphK2 (Section 2.1.3), we performed our studies
on the C4 domain of both isoforms. In this chapter, we report the results of protein
structure building followed by the docking studies of various reported Sphingosine
kinase inhibitors. Finally, a binding mode for K145 within the putative sphingosinebinding domain of SphK1 and SphK2 has been proposed.
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2.2 Methods

2.2.1 Structural Modeling of SphK1 and SphK2
2.2.1.1 Template Identification and Alignment
Human SphK1 (Accession: Q9NYA1) and SphK2 (Accession: NP_001191088)
sequences were obtained from the NCBI database (www.ncbi.nih.gov/protein/). A
Position Specific Iterated BLAST52,53 search against the database of Protein Data Bank
proteins was performed to identify a template structure. Diacylgycerol kinase from
Bacillus anthracis str. Sterne (PDB ID: 3T5P) was identified as the closest match to both
isoforms of SphK. Sequence alignments of each SphK1 and SphK2 with 3T5P were
performed using Clustal X v2.0.49 Unaligned regions in both the proteins were deleted.
2.2.1.2 Homology Modeling and Refinement
A total of 100 homology models for each isoform were generated based on these
alignments, using the automodel class of MODELLER 9v10.54 A DOPE (Discrete
Optimized Protein Energy) Score55 and a GA341 Score56 was calculated for each model
using MODELLER. The top 5 models for each kinase with lowest DOPE scores and
molpdf scores (a MODELLER object function score) and with GA341 scores closest to 1
were chosen for further refinement. The side chains for each model were optimized
using SCWRL57 (dunbrack.fcc.edu/scwrl4/). Hydrogens were added to these top models
using SYBYL v8.1 (TRIPOS Inc.) and subsequently subjected to Powell minimization for
10000 iterations in Tripos force field with a 0.005 kcal/mol-Å termination gradient. The
quality of minimized models was evaluated using MolProbity,58 which performs an allatom contact analysis to give a ‘clashscore’ that is indicative of the number of serious
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clashes (>0.4 Å) per 1000 atoms. Poor side-chain rotamers and unreasonable bond
lengths and angles were checked. Ramachandran plots were also generated using
MolProbity to check the backbone-geometry of the models. Atom clashes and bad bond
lengths and angles were optimized with further minimization. Sphingosine, the natural
substrate for both kinases, was docked into the C4 domain (putative Sph binding
domain, L163 – F197 for SphK1 and C329 – V363 for SphK2) of each model, using
GOLD v5.1.59 The docked poses were scored using HINT.60 The “best” model of both
SphK1 and SphK2 was then chosen based on its overall stability and its ability to
accommodate Sphingosine in its C4 domain.

2.2.2 Inhibitor Docking
The optimized models of both SphK1 and SphK2 were used for the docking
studies. The structures of inhibitors were sketched using SYBYL v8.1, and subjected to
minimization to get a low energy structure. The docking simulations were performed
using GOLD v5.1. The binding site was defined to encompass all atoms within 20 Å of
CA of Asp178 of SphK1 (Asp344 of SphK2). Fifty solutions for each inhibitor molecule
were generated with a protein hydrogen-bond constraint that the carboxylate of Asp178
of SphK1 (Asp344 of SphK2) forms a hydrogen bond with ligand, since the Asp is
important for recognition of sphingosine (Section 2.1.4). The docked poses were scored
using HINT. The poses with the best HINT scores were complexed with the protein and
the protein-ligand complex was subjected to minimization (2500 iterations, termination
gradient of 0.005 kcal/mol-Å), to remove steric clashes and get an induced-fit model.
The binding modes of the ligands after minimization were re-scored using HINT.
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2.3 Results and Discussion

2.3.1 Structural Modeling of SphK1 and SphK2
Since no crystal structure is currently available for either SphK1 or SphK2, we
generated their structural models using MODELLER, a comparative protein structuremodeling program. First, a PSI-BLAST search was performed against the database of
PDB proteins that identified a structure of Diacylglycerol kinase from Bascillus anthracis
str. Sterne (PDB ID: 3t5p) as the template (Figure 2.11). The template structure shares
~25% sequence identity and ~46% homology in the aligned regions to both SphK1 and
SphK2. The primary amino acid sequences were aligned using Clustal X v2.0, the
results of which are shown in Figure 2.12 and Figure 2.13.
Based on the sequence alignment, structural models of both isoforms of SphKs
were generated using MODELLER. The program sets up spatial restraints on Cα-Cα
distances, main chain N-O distances and main chain and side chain dihedral angles
obtained from the template crystal structure,54 which is followed by modeling all nonhydrogen atoms by violating these restraints as little as possible. The natural substrate
for SphKs, sphingosine, was docked into the C4 domain of top 5 models of each kinase
(based on lowest energy scores, refer Section 2.2.1.2) using GOLD (Genetic
Optimization for Ligand Docking). GOLD performs automated ligand docking, using
genetic algorithm to explore full ligand flexibility within the neighborhood of protein
binding site.59 The generated binding poses are ranked by a simple scoring function that
comprises of a hydrogen bonding term, a pairwise dispersion potential and a term for
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Figure 2.11 – Overall fold of the template structure – Diacylglycerol kinase from
Bascillus anthracis str. Sterne (PDB ID: 3t5p).
Image prepared using PyMOL.61
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Figure 2.12 – Sequence alignment of SphK1 with the template 3T5P (Diacylglycerol Kinase from Bacillus anthracis str.
Sterne).
Alignment performed using Clustal X v2.0. The alignment is colored based on the Clustal X color scheme (Appendix A.1).
Image prepared using Jalview.
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Figure 2.13 – Sequence alignment of SphK2 with the template 3T5P (Diacylglycerol Kinase from Bacillus anthracis str.
Sterne).
Alignment performed using Clustal X v2.0. The alignment is colored based on the Clustal X color scheme (Appendix A.1).
Image prepared using Jalview.
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internal energy of the ligand conformation.59 For our study, all the docked poses were
scored using the HINT force field, as it accounts for all the hydropathic forces involved
in the protein–ligand binding event. The “best” model of both SphK1 and SphK2 was
then chosen based on its overall stability and its ability to accommodate Sphingosine in
its C4 domain. Model044 was the best model for SphK1, with a clashscore of 3.2 (97th
percentile) and with 96.8% residues in allowed regions on Ramachandran plots.
Model055 was the best model for SphK2, with a clashscore of 2.03 (99th percentile) and
with 98.5% residues in allowed regions on Ramachandran plots. Figure 2.14 shows the
sphingosine-binding site of both SphK1 and SphK2.

2.3.2 Model Validation by Inhibitor Docking
The final optimized models for both proteins were further validated by docking a
panel of inhibitors including the reported SphK2 selective compounds shown in Figure
2.5, a SphK1 selective inhibitor, SK1-I,35 and FTY720, a compound known to bind to
both SphKs.62,63 Docking and scoring studies were performed as described in Section
2.2.2. As shown in Table 2.1, the HINT score results indicate that both FTY720 and its
o-methoxy derivative (R)-FTY720-OMe bind to SphK2 preferably, over SphK1. SK1-I
binds more favorably to SphK1, consistent with the reported biological results.35 We
also docked SG-12, ABC294640 and trans-12b (Figure 2.5); the relative ordering of
HINT scores (HTOTAL) are more or less in concordance with the reported
binding/inhibitory observations (Table 2.1).37-40 While specific HINT score values
generally should be calibrated for the specific biomacromolecular-ligand system,
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Figure 2.14 – Structural models of SphK1 (A) and SphK2 (B).
Both kinases are shown in cartoon representation, with their C4 domains in different
color. The docked sphingosine molecule is shown as sticks. Image prepared using
PYMOL.
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previous studies consistently indicate that Δ(HINT score)/ ΔΔGbinding ~ –515, i.e. HINT
score differences of around 515 correspond to 1 kcal/mol differences in binding
energies.64,65
Despite low overall homology to the template, there is considerable sequence
and structural similarity at the sphingosine-binding domain (C4 domain), and we believe
that these models will provide valuable structural information.

Table 2.1 – HINT Scores for docked molecules (previously reported inhibitors) into the
C4 domain of SphK1 and SphK2

Ligand

HINT Scoresa
SphK1

SphK2

FTY720

2347

2751

(R)-FTY720-OMe

138

1878

SG-12

1626

1876

ABC294640

-73

153

Trans-12b

-935

218

SK1-I

2080

679

a

Previous studies have shown that ~515 score units correspond to ΔΔG = -1.0 kcal/mol.
In the absence of a reference point from a calibration for this specific biomolecular
system, the HINT score difference between ligands and/or between SphK1 and SphK2
are more meaningful than their specific values.
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2.3.3 Proposed Binding Mode for K145
We then docked K145 to the two kinase models. The docking results revealed
that K145 binds preferentially to SphK2 (Table 2.2), as it shows more favorable
interactions in the sphingosine-binding pocket of SphK2 than that of SphK1.
Specifically, as shown in Figure 2.15, our model indicates that the terminal –NH2 of
K145 forms strong salt-bridge interactions with the carboxylate group of Asp344 (the
putative sphingosine recognizing residue). Other favorable hydrogen bonding
interactions are also formed between the guanidino-group of Arg351 and Gln346 with
the carbonyl oxygens of the TZD heterocycle. The TZD ring of K145 shows favorable πstacking interactions with Phe350 and the 4-butoxy-phenyl ring of K145 fits into a
hydrophobic pocket formed by the sidechains of Ala336, Val340, Val343, Arg617 and
Val619. K145 shows a very similar binding mode within the C4 domian of SphK1. The
terminal –NH2 of K145 forms salt-bridge interaction with Asp178 and the carbonyl
oxygen at 2-position of TZD rings forms hydrogen-bonding interaction with Arg185. The
TZD ring π-stacks with the aromatic ring of Tyr184 and the hydrophobic interactions of
the tail with the surrounding hydrophobic residues are more or less conserved. In
contrast to its binding mode in SphK2, the carbonyl oxygen at 4-position of the TZD ring
showed an unfavorable base/base interaction with the carboxylate group of Glu180 (that
corresponds to Gln346 of SphK2). Judging from the sequence similarity in the
sphingosine-binding domains of both isoforms, the GlnèGlu change in SphK1 is the
only significant difference in this region and might be the reason for K145 showing
selectivity towards SphK2.
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Table 2.2 – HINT Scores for K145 docked into the C4 domain of SphK1 and SphK2
HINT Score
Ligand
SphK1
SphK2
K145

1506

3011

Figure 2.15 – Binding mode of K145 in SphK1 (A) and SphK2 (B).
K145 is shown as sticks with carbon in green, while the interacting residues of both
kinases are shown as sticks with carbon in cyan. For simplicity, hydrogens are only
shown on residues forming hydrogen-bonding interactions with K145. Image prepared
using PyMOL.
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2.4 Conclusion
Dr. Zhang and his group identified a thiazolidine-2,4-dione analog, K145, as a
selective SphK2 inhibitor. Biochemical assays using recombinant SphK1 and SphK2
established that K145 selectively inhibited SphK2 and not SphK1.41 In absence of any
crystallographic data available for either isoform, we performed in-silico studies to gain
structural insights into protein-ligand interaction. We successfully generated structural
models of both sphingosine kinase isoforms, SphK1 and SphK2, using a known
structure of diacylglycerol kinase from Bacillus anthracis str. Sterne as the template
structure. K145 was then docked into the C4 domain of each model, and the proteinligand intermolecular interactions were elucidated using HINT scoring.
Although these are tentative models built from a kinase of bacterial origin, their
sphingosine-binding domains are more conserved than other regions, and the models
are more than adequate as hypothesis generators for compound design. Nonetheless,
our docking results do support the experimental assertion that K145 is a selective
SphK2 inhibitor.
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CHAPTER 3
HOMOLOGY MODELING OF HUMAN CYTOMEGALOVIRUS ALKALINE NUCLEASE
UL98 AND IDENTIFICATION OF POTENTIAL LEADS BY VIRTUAL SCREENING

3.1 Introduction
3.1.1 Human Cytomegalovirus (HCMV) – A human pathogen
Cytomegaloviruses, one of the major lineages in the Herpesviridae family, are
present in a wide range of mammalian species. Since they have a higher tendency to
infect the salivary gland, they are also termed as “salivary gland viruses”. Out of the
eight human pathogens belonging to Herpesviridae family, human cytomegalovirus
(CMV), also known as human herpes virus 5 (HHV-5), is the most extensively
characterized member. It is a prototypic member of this subfamily with a large doublestranded DNA genome of about 235 kbp in size, that consists of unique long and short
segments, each surrounded by inverted repeats.1
HCMV infection is existent in most populations around the world, with overall
HCMV seroprevalence ranging from 20%–100% in different countries. Higher
seroprevalence, nearly up to 100%, has been observed in individuals from resourceconstrained countries; in contrast, adults from well-developed countries from Northern
Europe
	
  

and

North

America

are

associated
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with

lower

rates

of

CMV infection.2 The overall age-adjusted CMV seroprevalence in the United States is
~50%.3
Infectious cytomegalovirus can be found in various body fluids like tears, saliva,
blood, urine and semen. CMV is spread easily with extended and repeated exposure to
virus in infants/young children attending day-care facilities, hospitalized patients and
hospital staff.4 Prolonged virus shedding from infected individuals seems to be a
common source of CMV acquisition in the community. CMV transmission easily occurs
by person-to-person contact or contact with contaminated surfaces. Infants, toddlers
and young children are an important reservoir of the virus. The virus is efficiently
transmitted among children attending the same child-care centers by constant physical
contact, hand-to-mouth contact or by limited personal hygiene practices. A susceptible
seronegative mother or a pregnant woman visiting the group care facilities is at a very
high risk of infection, which in turn leads to congenital CMV infection of the fetus4.
Lactating mothers act as a source of CMV to newborn babies due to ingestion of
infected breast milk.5 Infected children readily transmit the virus to adults. The shedding
of CMV virus via the genitourinary tract leads to its transmission among adults during
sexual activity.6 Sources of CMV in hospitalized patients include blood product
transfusions and transplanted organs from seropositive sources. Health-care workers
are also at a risk of acquiring infection since they are in such environments for
prolonged periods of time.
CMV infections acquired in healthy people are usually mild and asymptomatic,
and typically go unnoticed. On the other hand, CMV infections can have severe clinical
and
	
  

pathological

manifestations

leading
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to

life

threatening

conditions

in

immunocompromised patients, especially transplant recipients and HIV-positive
patients.7 CMV pneumonitis is a major cause of morbidity and mortality in severely
immunocompromised patients following solid organ transplantation or hematopoietic
stem cell transplantation, even with treatment.8 In HIV-infected patients, a CMV
infection causes serious ocular complications like retinitis, gastric complications leading
to hemorrhage/perforations, and in some cases neurological damage causing paralysis
or fatal encephalitis.9,10 Congenital and neonatal CMV infections are more serious and
in many cases are life-threatening. In newborns congenital CMV infections are the
leading cause of sensorineural hearing loss (SNHL), which may be present at birth or
develop later in childhood.11,12 CMV infections acquired during pregnancy have been
reported to cause learning disabilities and mental retardation.13 More recently, reports of
CMV infections in immunocompetent patients with prolonged and relapsing illnesses
involving fever, sweats, and in some cases abnormal liver functions, have been well
documented.14,15

3.1.2 Antiviral Therapy for CMV Infection
Over the past few years, major advances have been made in the treatment and
prevention of CMV infections by the development of antiviral agents. Currently available
licensed antivirals for CMV (Figure 3.1) include ganciclovir (Cytovene®), its valine ester
prodrug valganciclovir (Valcyte®), foscarnet (Foscavir®), cidofovir (Vistide®), and
Cytomegalovirus Immune Globulin (CytoGam®) (summarized in Table 3.1).
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Table 3.1 – Summary of currently licensed antivirals for CMV infections (adapted from ref 1,11).

Available Drug

Dose

Major Indications

Associated Toxicities

Ganciclovir
Cytovene®

10–12 mg/kg/day IV

Prophylaxis;
Congenital and perinatal CMV infection;
CMV retinitis;
End-organ disease in
immunosuppressed patients

Hematotoxicity (mainly neutropenia,
thrombocytopenia);
Carcinogenic;
Teratogenic

Valganciclovir
Valcyte®

–

Prophylaxis;
CMV retinitis

Identical to its active metabolite –
ganciclovir

90 mg/kg q 12h IV

Prophylaxis; CMV retinitis;
End-organ disease in
immunosuppressed patients with
ganciclovir-resistant infections

Nephrotoxicity;
Electrolyte imbalances;
Teratogenic

Cidofovir
Vistide®

5 mg/kg q weekly

End-organ disease in
immunosuppressed patients with
ganciclovir-resistant infections

Nephrotoxicity;
Ocular toxicity;
Carcinogenic;
Teratogenic

Cytomegalovirus
Immune Globulin
Cytogam®

100–150 mg/kg,
IV post-transplant

Prophylaxis;
Adjunctive treatment for CMV pneumonitis
in immunocompromised patients

Minimal toxicity

Foscarnet
Foscavir®
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Ganciclovir (and its prodrug – vanciclovir) is a guanosine analog, which upon
phosphorylation by the CMV UL97 kinase, acts as a chain terminator during viral DNA
replication. Ganciclovir therapy is the treatment of choice for CMV related retinitis and
pneumonitis

in

transplant

patients.16-18

Foscarnet

is

a

structural

analog

of

pyrophosphate and inhibits the CMV DNA polymerase by binding at its pyrophosphatebinding site and halts DNA chain elongation. DNA modifying enzymes in CMV produces
pyrophosphate as one of the products, thus making Foscarnet a product inhibitor; and
so unlike ganciclovir, it does not compete with natural nucleotides. It does not require
activation by the phosphorylative enzymes of either the host or the virus. Foscarnet is
an effective second-line treatment for CMV infections in HIV-patients and in cases
which develop ganciclovir resistance.19 Cidofovir, like foscarnet, is a second-line therapy
antiviral. It is an acyclic deoxycytidine monophosphate analog, which upon conversion
to diphosphoryl metabolite by cellular enzymes inhibits the CMV DNA polymerase.20
Cytomegalovirus Immune Globulin is an intravenous immunoglobulin preparation that is
indicated for prophylaxis against CMV infections in transplant recipients. It is prescribed
either alone, or in combination with any of the above-mentioned antiviral agents.11
All of the above drugs share a similar mechanism of action, i.e., inhibition of viral
DNA polymerase and interfering with its DNA synthesis process. There are also
significant toxicities associated with each of these drugs. In immunocompromised
patients,

ganciclovir

is

associated

with

bone

marrow

suppression,

mainly

granulocytopenia and thrombocytopenia. Ganciclovir, when used for a prolonged period
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of time, is considered a potential human carcinogen, teratogen, and mutagen.21 The
most important clinical problem that may emerge during foscarnet/cidofovir therapy is
nephrotoxicity.22,23 Although suited for prophylaxis and treatment of CMV related
infections in adults, evidence of teratogenicity in lab animals makes these drugs not
ideal for treatment in pregnant women.24 Also, there is limited evidence for using these
antivirals to treat congenital and perinatal HCMV infections.25 Patients receiving
prolonged therapy are at the risk of developing resistance to these antivirals.26 A
ganciclovir resistance study, on a group of AIDS patients suffering from CMV retinitis by
Jabs D. A., et al., showed that about 11% of the patients developed resistant-strain
virus within 6 months of treatment, and about 28% by 9 months.27 Being structurally so
similar, it would be expected that a virus resistant to one compound would exhibit crossresistance to others.
Although these antiviral drugs have been useful in treating a range of CMVrelated infections, the toxicities and chance of developing resistance associated with
them emphasize the need for developing less toxic novel antivirals, especially those that
target alternate processes essential for viral survival. Safer, nonteratogenic antivirals
could be used during pregnancy to treat fetal infections or in neonates to prevent CMV
related mental retardation and SNHL.
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3.1.3 HCMV Alkaline Nuclease UL98 – A novel target
The general idea behind developing antivirals against CMV is to identify and
disable viral proteins that are important for its development. Novel compounds targeting
different processes are desirable because of their potential to be used in combination
therapy and to avoid resistant-strain viral development. Alkaline nucleases, encoded in
all herpes viruses, represent one such target.
The herpesvirus alkaline nucleases are DNA-modifying enzymes that possess
both 5’ – 3’ exonucleolytic activity and a slightly moderate endonucleolytic activity.28
They have a high in vitro pH optimum and hence are termed “alkaline”. These enzymes
can process both single-stranded and double-stranded DNA substrates, with a notable
preference for supercoiled substrates. Different members of the Herpesviridae family –
viz. Herpes Simplex Virus (HSV), Cytomegalovirus (CMV), Kaposi’s Sarcoma
associated herpesvirus (KSHV) and Epstein-Barr Virus (EBV), encode the alkaline
exonuclease. The majority of data on the biological role of these enzymes at different
stages of viral development comes from studies on Herpes Simplex Virus type I (HSV1) Alkaline Nuclease – UL12, which is the first described, expressed and mapped
herpesvirus alkaline nuclease.29 Although the exact function of alkaline nucleases in
viral survival is unknown, studies have shown that HSV-1 AN is required for efficient
processing of viral DNA replication intermediates, suggesting its role in maturation and
packaging of viral DNA into capsids.30 Additional reports have indicated the importance
of HSV-1 AN in the efficient egress of capsids from the nucleus.31
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Different genes involved in viral DNA replication, cleavage and packaging, are
highly conserved among HSV-1 and CMV32; even though the HSV-1 genome is
significantly smaller in size (~150 kb compared to ~235 kb of CMV). Predictions based
on gene arrangement and amino acid sequence homology have indicated the HCMV
UL98 gene to be the counterpart of HSV-1 UL12 gene. Trans-complementation
experiments have demonstrated functional conservation of proteins encoded by the
homologous genes of HSV1 and CMV.33 The UL98 protein encoded by the CMV UL98
gene is indeed the conserved enzyme homolog of α- and γ- herpesvirus alkaline
nucleases.34
In vitro, HCMV UL98 AN shows both 5’ – 3’ exonuclease (exo) and
endonuclease (endo) activities that are optimal at alkaline pH, similar to other ANs. It
also can hydrolyze dsDNA and ssDNA substrates and requires a divalent cation for
activity, with preference for magnesium ion.34 The role of UL98 alkaline kinase in CMV
infection is extremely important, suggested by the fact that its synthesis starts at early
stages of infection, with significant increase in its levels after the onset of viral DNA
replication.35 In more recent studies, the global functional analysis of HCMV genome
has identified the UL98 gene, which encodes the UL98 AN, as essential for viral
growth.36,37 The fact that HCMV UL98 gene complemented an HSV-1 UL12 deletion
mutant functionally can be used to assume a similar role of UL98 alkaline nuclease in
CMV DNA modification, capsid stability and egress.33 Although the alkaline nuclease is
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not required for viral DNA synthesis,38 there is enough evidence to emphasize the
importance of UL98 AN in the different stages of CMV viral development.
The plausible impact of UL98 AN on CMV viral growth, and the presence of an
alkaline nuclease homologue in every herpesvirus, makes it a unique antiviral target for
CMV infections. Unlike traditional approaches that target viral DNA synthesis by
inhibiting DNA polymerase, this approach targets the late events in viral replication like
viral DNA packing, capsid stability or egress. This would be beneficial to treat resistant
infections and also prevent their occurrence with combination therapy. Also, identifying
novel inhibitors of UL98 AN may help to overcome the modest antiviral activity of
currently approved drugs and their dose-related toxicities, and result in a highly
efficacious antiviral therapy, intended to be used in patients of all ages and conditions
(infants, adults, pregnant women, transplant recipients, AIDS patients).

3.1.4 Alkaline Nucleases – Structural insights
A phylogenetic analysis, by Rychlewski, L., et. al., has classified the herpesvirus
alkaline nucleases within the PD-(D/E)XK superfamily of DNases39. This family includes
structurally

well-characterized,

functionally

diverse

members

like

restriction

endonucleases40 (EcoRI and EcoRV), DNA-nicking enzymes (Vsr41 and MutH42), and
bacteriophage λ exonuclease43 (λ-exo). Although these enzymes share little overall
sequence similarity, they have a common core fold and a conserved, well-defined
PDX10-30(D/E)XK motif that is involved in metal-binding and catalysis. The central core
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region is formed of four-stranded, mixed β-sheets flanked by two α-helices on either
side, with αβββαβ topology (Figure 3.2). The catalytic sites of these enzymes contain a
conserved aspartic acid (D), an aspartic or glutamic acid (D/E) and a lysine (K).44 To
date, crystal structures of two herpesvirus alkaline nucleases have been solved – the
Kaposi’s sarcoma-associated herpesvirus Shut-off and Exonuclease45 (KSHV-SOX) and
its Epstein-Barr virus (EBV) homolog BGLF5.46 They confirm the structural similarity of
herpesvirus ANs to the PD-(D/E)XK superfamily, sharing a comparable central core fold
and active-site formation.
Very little is known about the structure of CMV UL98 alkaline nuclease, apart
from the fact that it too is a herpesvirus alkaline nuclease, and therefore should be
structurally similar to proteins of PD-(D/E)XK superfamily. The knowledge of the threedimensional structure of UL98 AN is required for better understanding of its functional
mechanism and to elucidate its exact role in virus growth and development. The recent
computational advances in homology protein structure modeling have enabled reliable
prediction of unknown protein structure based on a homologous protein of known
structure. The model can then be potentially used for structure-based design of a novel
class of antiviral drugs.
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Figure 3.2 – The conserved PD-(D/E)XK core fold with active site formation (Reprint
from ref 44).
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3.1.5 Specific Aims
In the current work, we aim at identifying novel antiviral agents that target CMV
UL98 AN using traditional computational approaches like homology modeling and 3D
virtual screening on the protein model. The working hypothesis that underlies this
project is that the nuclease activity of UL98 is critical for HCMV viral development and
targeting it may lead to a novel, efficacious antiviral therapy for CMV infections, with
reduced toxicities. The work has been divided into two specific aims:
1) Structural modeling of CMV UL98 AN, and
2) Virtual screening on the active-site of UL98 AN model
The first part of this work involved homology-based structural modeling of UL98
AN in order to identify the active-site residues. The active-site residues were validated
using mutagenesis, in the lab of Dr. Michael McVoy, Professor of Pediatrics, Molecular
Biology and Genetics, School of Medicine, VCU. Mutant viral construction was also
performed to show the importance of UL98 in CMV replication. The computational work
has been described in detail in the following sections, and the findings have been
recently published (Kuchta et al).47
The second part of the work involved structure-based drug discovery on the
UL98 AN model with an aim to identify novel small-molecules that might inhibit its
nuclease activity. We have performed 3D virtual screening on the active site, the results
of which will be discussed in detail in the following sections.
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3.2 Methods

3.2.1 Structural Modeling of HCMV UL98 AN
3.2.1.1 Template Identification and Alignment
PSI-BLAST (Position-Specific Iterated BLAST)48,49 was performed on the amino
acid sequence of HCMV UL98 AN (strain AD169) using the PDB Protein Database to
identify a template structure based on which its structure can be built. The first Expect
value (E-value) was set to 1 for the initial BLAST search and the second E-value, which
is the threshold value for inclusion in the position specific matrix (BLOSUM62) used for
PSI-BLAST iterations, was set to 0. The Shutoff and Exonuclease Protein from KSHV
(KSHV-SOX) (PDB ID: 3FHD)45 was chosen as the “template” structure for model
building, based on its max score of 104 and E-value of 1e-22. Clustal X v2.050 was used
to align the amino acid sequence of UL98 AN (query sequence) with the sequence of
KSHV-SOX (template). The active site and the 5’ phosphate binding residues in UL98
AN were identified based on their alignment with corresponding residues of KSHV-SOX.
3.2.1.2 Homology Modeling of UL98 AN
The homology model of UL98 AN was constructed based on the available crystal
structure of KSHV-SOX (PDB ID: 3FHD) and the sequence alignment obtained from
Clustal X v2.0 using Comparative Modeling Program MODELLER 9v7.51-54 MODELLER
sets up spatial restraints on Cα-Cα distances, main chain N-O distances and main chain
and side chain dihedral angles obtained from the template crystal structure.51 A total of
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100 models were generated using the automodel class of MODELLER, which builds
models by violating these restraints as little as possible. The final model was selected
based on its ability to accommodate a DNA fragment in its active site crevice.
3.2.1.3 Docking of dsDNA into the active site of UL98 AN
Protein structure preparation. From all 100 generated models, the unaligned
regions that were built by MODELLER without a template were deleted using the
general molecular modeling program SYBYL v8.1 (TRIPOS Inc.); i.e., residues Met1Glu25, Arg83-Ile90, Thr344-Leu355, Lys381-Ser419, Asp431-Val446, and Ser569Pro584. The region starting at Asp189 and ending at Phe211, which is near the active
site, aligned with ‘the bridge’ region of the template (Pro164-Phe179), which could not
be crystallized owing to disorder,45 was deleted from the alignment. All the other regions
that were deleted were distant from the active site crevice of UL98 AN and should not
affect later modeling in this region. Hydrogens were added to all the protein structures,
charges were calculated by the Gasteiger-Hückel method, and all models subjected to
Powell minimization for 1000 steps, keeping the coordinates of all non-hydrogen atoms
fixed.
Substrate preparation. A B-DNA dodecamer (PDB ID: 3BNA) was chosen as the
ligand to be docked into the active site crevice of UL98 AN homology models using
GOLD v4.1. Since this ligand was too big, a 4bp long dsDNA fragment (A-C-G-T) was
built in SYBYL v8.1 (TRIPOS Inc.), and used as a reference ligand for docking. The
positions of the 5’-phosphate group and the phosphodiester bond joining the final two
	
  

79

bases as predicted by GOLD, were then used to overlay the corresponding groups of
3BNA in order to get the final protein-ligand complex.
Docking. The ACGT reference ligand was docked into the active site crevice of
all MODELLER generated UL98 AN homology models using GOLD v4.1. The binding
site was defined to encompass all atoms within a 15 Å radius of Oδ1 of Asp254, which
is located at the center of the active site. All rotatable bonds, except terminal, in the
ACGT reference ligand were fixed to make sure that GOLD would not disrupt the double
stranded helix structure by rotating the other bonds in the ligand structure to find a
better binding mode. Default Genetic Algorithm parameters were used. A total of 30
solutions were generated for each UL98 AN homology model. The solutions for each
model were scored and ranked using the GOLD Fitness Scoring Function. Only 8 out of
all the homology models gave positive GOLD Fitness Scores, suggesting that the other
models were unable to accommodate the ACGT ligand. The binding modes of the
ACGT ligand in the remaining 8 models were visually analyzed to see which UL98 AN
model was best able to accommodate the reference ligand and explain its exonuclease
activity. HCMV UL98 AN homology model065 was chosen, as it was best able to
accommodate the 5’ phosphate group among all the models. This final model was
subjected to further refinement. The 5’ phosphate group and P2 group of 3BNA were
overlaid onto the positions of the corresponding groups in the ACGT reference ligand, in
its best conformation for UL98 AN model065 as predicted by GOLD, in order to obtain
the best possible conformation for 3BNA in the active site of UL98 AN.
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3.2.1.4 Final UL98 AN Model – Refinement and Validation
UL98 AN model065 was evaluated using the DOPE (Discrete Optimized Protein
Energy) scoring function55 and GA341 assessment score,56 incorporated within
MODELLER 9v7. A DOPE per-residue score was calculated for this model065 and
compared to that of the KSHV-SOX crystal structure.
KSHV-SOX is a PD-(D/E)XK nuclease that uses a magnesium ion and a water
molecule for activity.45 The relative coordinates of a putative active site magnesium ion
and water molecule for UL98 AN model were obtained from the crystal structure of
KSHV-SOX, by aligning their structures based on homology within SYBYL v8.1.
Model065, now containing active site magnesium ion and water molecule, was
complexed with 3BNA (in a position analogous to the best conformation of the ACGT
reference ligand). The side-chain of Ser252 in the active site of UL98 AN was manually
rotated towards the 5’ phosphate group to show better interaction, mimicking the
position of the corresponding active site Ser219 of KSHV-SOX. This protein-ligand
complex was then subjected to Powell Minimization to a gradient of 0.005 kcal mol-1 Å-1
to account for any steric clashes and to obtain an induced fit model of UL98 AN with its
substrate. Following minimization, all the ligands were deleted from the protein and
Ramachandran plots were calculated using MolProbity.57
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3.2.1.5 Multiple Sequence Alignment of Herpesvirus ANs
In order to check that the active site residues identified for HCMV UL98 AN are
conserved within other Herpesviridae ANs, the primary amino acid sequences for
Herpesvirus ANs, including Human Cytomegalovirus (HCMV) Alkaline Nuclease UL98,
ORF37 of Kaposi’s Sarcoma Associated Herpesvirus (KSHV) (ABD28888), BGLF5 of
Epstein-Barr Virus (EBV) (ABB89261), U70 of Human Herpesvirus 6 (HHV6) (NP050249), U70 of Human Herpesvirus 7 (HHV7) (AAC40784) and UL12 of Human
Herpesvirus

1

(HHV1)

(BAA84005)

were

obtained

from

the

NCBI

(http://www.ncbi.nlm.nih.gov/) and aligned using Clustal X v2.0.50
3.2.1.6 Estimation of Changes in Free Energies of Association of UL98 AN with dsDNA
upon Mutation
Intermolecular interactions between the UL98 AN and dsDNA (3BNA), in their
minimized complex form, were calculated using HINT (Hydropathic INTeraction). The
HINT score (Htotal) was calculated and converted to free energy using the equation:
ΔGbinding = − 0.00195Htotal − 5.543.58 The structures of mutants of UL98 AN (R164A,
S252A, D254A, E278A and K280A) were generated within the structure of UL98 –
dsDNA complex, using SYBYL 8.1 and Htotal scores were calculated for each mutantligand pair, and subsequently converted to ΔGbinding free energy values. On the basis of
the predicted ΔGbinding for each UL98 mutant, ΔΔGbinding values of differences in free
energy between wild type and each UL98 mutant were calculated.
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3.2.2 Validation of UL98 AN Model using Mutagenesis
All the experimental work was performed in Dr. Michael McVoy’s lab (Department
of Pediatrics, Virginia Commonwealth University, VA) and Dr. Deborah S Parris’s lab
(Department of Molecular Virology, Immunology and Medical Genetics, The Ohio State
University, OH). For detailed experimental procedures, please refer to our recent
publication – Kuchta, A., et al.47 Briefly, recombinant UL98 and proteins containing
single alanine substitutions (R164A, S252A, D254A, E278A or K280A) were expressed
with amino-terminal hexahistidine (His6) tags. The proteins were expressed and
partially purified by immobilized metal affinity chromatography (IMAC). The exo
activities of the IMAC-purified proteins were quantified by release of acid-soluble
radioactivity from

14

C labelled DNA. Endo activity was determined qualitatively by

incubating IMAC-purified proteins with closed-circular pUC19 plasmid DNA and
evaluating its conversion to open-circular and linear forms by agarose gel
electrophoresis. To quantify endo activity independent of exo activity, a fluorescencebased assay was developed in which fluorescence increases when endonucleolytic
cleavage of an ssDNA substrate releases a 3’ quencher from a 5’ fluorophore.

3.2.3 3D Virtual Screening on the Active-Site of UL98 AN Model
The model of UL98 AN – dsDNA complex was used to identify the important
molecular interactions involved in the association. These were used as the basis to
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generate a pharmacophore model describing features desirable in ligands that might
bind at the active site and inhibit its activity.
3.2.3.1 Design of Query
The UNITY module within SYBYLx1.2 (http://www.tripos.com/) was used to
create a 3D query that can be used to scan databases of diverse chemical compounds.
A “negative center”, sphere of 1 Å radius, with the center at a position analogous to the
5’ phosphate atom, was defined. A “donor atom” feature was defined at a position near
the catalytic metal, sphere of 0.5 Å radius, such that any hydrogen-bond donor group in
the ligand would engage the carboxylate groups of D254 and E278 residues and disrupt
the enzyme’s catalytic activity. Another feature defined in the catalytic region was an
“acceptor atom”, sphere of 0.5 Å radius, complementary to K280. A central “aromatic
hydrophobic” core region, sphere of 1.5 Å radius, was defined in the vicinity of the
deoxyribose ring of the first nucleotide. Next, a distance constraint, with a tolerance of
±0.5Å, was set up between the negative center and the donor atom. Finally, receptorsite constraints were defined around heavy atoms of the protein surrounding the cavity.
The generated 3D query was used to screen a library of over 250,000
compounds

belonging

to

the

National

Cancer

Institute

Open

Database

(http://cactus.nci.nih.gov/ncidb2.1/). A “flexible 3D search” that uses a torsional
minimizer was performed. This technique identifies molecules that might fit the defined
query. Also, all the compounds are screened for their drug-like properties based on
Lipinski’s rule of five.59
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The entire data mining process reduced the candidates to a more manageable
number, all of which were subjected to docking into the active site of UL98AN.
3.2.3.2 Docking of Hits
The hits obtained at the end of first stage of screening were docked into the
active site of UL98 AN using GOLD v5.1. This approach leads to identification of hits
having a better fit in the active site, along with all the structural features necessary for
binding. Before this step, all the hits were visualized to check for incorrect atom-types,
bond-types, unsatisfied valencies; all such were corrected if necessary, and saved in a
ready-to-dock, 3D format. The binding site was defined to encompass all atoms within
15 Å radius of Oδ1 of Asp254, which is located at the center of the active site. Default
genetic algorithm parameters were used. A total of 100 solutions per ligand were
generated (no early termination, no constraints) in order to obtain multiple poses within
the binding site.
3.2.3.3 Scoring of Docked Poses
To identify the most likely binding mode of a ligand within UL98 AN active site,
out of all possible solutions generated from docking, each protein-ligand complex was
scored using the HINT forcefield. Unlike the default scoring function of the docking
software, HINT scores are known to correlate with the binding free energy.58,60,61 The
binding modes of the top scored solution for each ligand was visually analyzed. Hits that
showed significant interaction with the important residues of the active site (R164, S252,
D254, E278, K280) were retained.
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3.3 Results and Discussion

3.3.1 The Template – Kaposi’s Sarcoma Associated Herpesvirus Shut-off and
Exonuclease (KSHV-SOX)
Herpesvirus ANs are classified within the λ exo family of DNases, which is within
the PD-(D/E)XK superfamily of DNA-modifying enzymes.43 The catalytic sites of these
enzymes contain a conserved aspartic acid (D), an aspartic or glutamic acid (D/E) and a
lysine (K). To identify a potentially related sequence of known structure that can be
used as a template to build the structure for UL98 AN, PSI-BLAST was performed on
the primary amino acid sequence of UL98 using the PDB Protein Database. The Shutoff
and Exonuclease Protein from Kaposi’s Sarcoma Associated Herpesvirus (KSHV-SOX)
(PDB ID: 3FHD), which belongs to the same PD-(D/E)XK superfamily of proteins, was
the closest structural match identified, and shares 26% sequence identity and 40%
homology with it. The catalytic residues of KSHV-SOX are D221 and E244, which
coordinate Mg2+, and K246, which stabilizes the leaving group.45 An adjacent 5’phosphate-binding pocket formed by R139, S146 and S219 was suggested by the
presence of a sulphate ion in the crystal structure.45 Figure 3.3 shows the overall fold of
KSHV-SOX and its active site residues.
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Figure 3.3 – Template structure KSHV-SOX (PDB ID: 3fhd).
The catalytically important Mg2+ ion (green sphere) and sulfate ion (sticks) at a position
analogous to 5’ phosphate binding site. The inset shows the active-site residues (shown
as sticks) that are involved in coordination of sulfate ion and Mg2+ ion. Image prepared
using PyMOL.62
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3.3.2 HCMV UL98 AN Model
Pairwise sequence alignment between the UL98 AN primary amino acid
sequence and that of KSHV-SOX was performed using Clustal X v2.0, which helped to
identify the regions of similarity (Figure 3.4). Amino acids D254, E278 and K280 of
UL98 AN are the corresponding catalytic residues, and R164, T171 and S252 form the
putative 5’-phosphate-binding pocket.
A structural model of UL98 was constructed based on the crystal structure of
KSHV-SOX and in silico docking was used to determine the optimal binding of a dsDNA
dodecamer in the predicted UL98 binding site crevice.
A total of 100 models of UL98 AN were generated using the comparative
homology modeling program MODELLER 9v7, based on the sequence alignment with
KSHV-SOX. The docking was initially performed using a 4 bp long nucleotide (ACGT)
as the reference ligand. The most reasonable accommodation of the ligand in the active
site was shown by model065. The model shows that 5’ phosphate end is held in place
deep into the active site crevice through strong hydrogen bonding interactions with side
chains of Arg164 and Ser252 and weak interactions with the backbone of Ala170 and
Thr171. Also, the phosphodiester bond, where nucleophilic attack takes place for
hydrolysis, is situated very close to Asp254, Glu278 and Lys280, which is the metal
coordination site.
Model065 was evaluated using the Discrete Optimized Protein Energy (DOPE)
scoring function and GA341 assessment score within MODELLER 9v7. DOPE per	
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Figure 3.4 – UL98 AN amino acid sequence in pairwise alignment with KSHV-SOX,
using Clustal X v2.0.
Asterisks indicate putative active site residues and the default Clustal X v2.0 color
scheme is applied. Apparent insertions in UL98 AN relative to KSHV-SOX (lower case)
and residues that align with a region in KSHV-SOX that did not crystallize (grey box)
were deleted from the UL98 model. Figure prepared using Jalview,63,64 sequences
colored using the default Clustal X color scheme (Appendix A.1).
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residue scores calculated for both model065 and 3FHD indicated that model065 depicts
UL98 AN in a native-like form, as the two DOPE profiles were similar in the active site
region. The GA341 method, which uses percentage sequence identity with the template
as a parameter to assess the quality of the predicted model and ranges from 0.0 (worstmodel) to 1.0 (native-like), yielded a score for model065 of 0.9999.
The coordinates for a putative Mg2+ ion and active site water molecule for
model065 were obtained by aligning the template structure to the model. The proteinligand complex was then subjected to an all-atom minimization to a gradient of 0.005
kcal mol−1 Å−1 to account for steric clashes and to obtain an induced-fit model of UL98
with its substrate. All the ligands were then deleted from the model and Ramachandran
plots were calculated using MolProbity. 83.1% of the residues were in the favored
region and 96.8% of residues in the allowed region (Figure 3.5). Out of 438 residues,
there were 14 outliers; each was visually inspected and all were found to reside in
regions remote from the active site region.
The final UL98 AN structural model was generated following refinement
(discussed above) on model065. Figure 3.6 shows the overall structural fold of the
protein, comprising an amino-terminal domain consisting of ten α-helices and a carboxyterminal domain formed by five-stranded β-sheets flanked by five α-helices. The
putative Mg2+ ion and the active-site water molecule are also shown, along with the
active-site residues.
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Figure 3.5 – Ramachandran plots for UL98 AN homology model as determined by
MolProbity. Outliers are shown in colors.
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Figure 3.6 – UL98 AN Model.
Active site residues are shown in blue sticks. The catalytically important Mg2+ ion and
water molecule are shown as spheres. Image prepared using PyMOL.
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Guided by the positions of the 5’ phosphate group and the P2 group, the
structure of crystallized dsDNA (PDB ID: 3BNA) was overlaid on ACGT reference ligand,
in its best-docked position within the active site crevice of HCMV-UL98. The predicted
position of DNA shows the 5’ phosphate held deep into the active-site crevice through
hydrogen bonding with R164 and S252. The scissile phosphodiester bond is
appropriately positioned proximal to the metal coordination region formed by D254,
E278 and K280 (Figure 3.7).
Important active site residues should be strongly conserved within the
Herpesviridae ANs. Previous alignments have identified seven amino acid motifs that
are conserved among ANs from the α-herpesvirus subfamily and extend to ANs from
the β and γ-herpesvirus subfamilies.65 To determine if the five residues predicted by
structural modeling are conserved, amino acid sequences for ANs representing all three
subfamilies were aligned using Clustal X v2.0 (Figure 3.8). The putative active site was
found to span motifs II and III. Residues Arg164, Ser252, Asp254, Glu278, and Lys280
were fully conserved.
Active-site models for DNA interactions of wild-type and mutant UL98 proteins
were generated from the UL98 model. Fig. 3.9 shows predicted active-site structures for
wild-type UL98 and each of the five mutants. Loss of hydrogen-bonding interactions
resulting from substitutions R164A or S252A may result in imprecise alignment of the
DNA in the active site, resulting in improper positioning of the scissile phosphodiester
bond relative to the catalytic K280 residue (Figure 3.9(B) and 3.9(C)). This was further
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Figure 3.7 – UL98 AN active site model (residues – carbons in cyan; dsDNA – carbons
in green).
Mg2+ (green sphere) is coordinated by the carboxylate groups of D254 and E278 and
holds the water molecule (red sphere) at the active site. K280 is proximal to the
phosphodiester group and the 5’ phosphate shows strong hydrogen-bond interactions
with side chains of R164 and S252. Image prepared using PyMOL.
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Figure 3.8 – Multiple sequence alignment between Herpesvirus alkaline nucleases.
Asterisks indicate active-site residues that are fully conserved among the entire family. Figure prepared using Jalview,
sequence colored using the default Clustal X color scheme (Appendix A.1).
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supported by significant changes in the predicted DNA-binding energies for R164A,
S252A and K280 mutants (Table 3.2). Similarly, the loss of charged carboxylate
residues in D254A or E278A mutants would result in failure to coordinate the
magnesium ion and water molecule (Figure 3.9(D) and 3.9(E)). Changes in predicted
DNA-binding energies for mutants D254A and E278A are minimal (Table 3.2),
consistent with these residues interacting with Mg2+ rather than by directly interacting
with the DNA. The K280A mutation would be unable to carry out the hydrolysis of the
phosphodiester bond and stabilize the leaving group (Fig. 3.9(F)).

Table 3.2 - HTOTAL scores and corresponding ΔΔGbinding energies calculated for wild-type
and UL98 AN mutants

	
  

Protein

HTOTAL

ΔΔGbinding (kcal mol-1)

WT

5401

0.00

R164A

3190

4.31

S252A

4159

2.42

D254A

5267

0.26

E278A

5303

0.19

K280A

3204

4.28
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Figure 3.9 – Active site models for DNA interactions of wild-type and mutant UL98.
Active site residues are shown as sticks with carbon atoms in cyan, the DNA is shown
as sticks with carbons in green. Image prepared using PyMOL.
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The region starting at Asp189 and ending at Phe211 in UL98 AN, the bridge
region that connects the N-terminal domain to the C-terminal domain, was not modeled
due to its absence in the template owing to disorder. There have been suggestions that
the bridge architecture plays an important role in exonucleolytic cleavage by inducing
strand separation.46,66 The bridge region is also proposed to promote endonucleolytic
processing by developing local regions of ssDNA within the substrate, which are the
likely targets for endo cleavage. However, the high degree of disorder in the structure of
the bridge region in both KSHV-SOX and the KSHV-SOX–DNA complex structures
made it difficult to model the corresponding region in UL98. Thus, our modeling focused
on the active-site region and cannot be extrapolated to the role of ‘the bridge’ in the
functions of UL98.

3.3.3 Validation of UL98 AN Model using Mutagenesis
The experimental data are generally consistent with the modeling predictions.
For details, please refer to our recent publication – Kuchta, A., et al.47
All of the single-alanine mutant proteins failed to digest substantial amounts of
substrate DNA in a one hour period. Exo activity of the R164A mutant was 10.6% of
wild-type and statistically higher than those of the other mutants and GUS (negative
control); whereas activities for D254A, E278A, K280A and S252A were <5% that of
wild-type and not statistically different from each other or from GUS (Figure 3.10).
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For the D, E or K è A mutants, endo activity was greatly reduced, but low level
activity was still apparent with the supercoiled dsDNA substrate. Although D254A and
E278A preparations were able to convert some of the supercoiled DNA into opencircular and full-length linear DNA, the majority of the supercoiled DNA substrate
remained intact after the 12 hour incubation. In contrast, the K280A and S252A mutant
proteins nicked essentially all of the supercoiled DNA, although large amounts of nicked
open-circular and full length linear forms remained undigested. Following 12 hour
incubation, the wild-type and R164A proteins were not only capable of nicking the
supercoiled substrate, they had degraded all of the DNA substrate, presumably to
products too small to visualize on the gel.
The quantitative fluorescence-based assay showed no significant difference
between the endo activities of R164A and wild-type UL98 and both wild-type and
R164A endo activities were significantly different from those exhibited by GUS and the
other mutant proteins. The activities of S252A, D254A or E278A were not different from
each other or from GUS (Figure 3.11).
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Figure 3.10 – UL98 AN mutants – Exo activity.
(a) Exo activities were determined as acid-soluble radioactivity released during
incubation of 14C-labelled DNA with 2.5 µg of IMAC-purified UL98 WT or UL98 R164A.
(b) Exo activities of mutants were measured after one hour incubation. Data are means
of disintegrations per minute obtained from three experiments. Error bars represent
means ±1 SD.
* R164A differs from GUS and other mutants; unpaired t-test, P ≤ 0.05
Reprint from ref 47.
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Figure 3.11 – UL98 AN mutants – Endo activity.
(a) Supercoiled plasmid DNA (250 ng) was incubated for 12 hours with buffer only (ϕ),
5 µg of IMAC-purified protein of 1 U of DNase I. Products were analyzed by agarose gel
electrophoresis. Arrows indicate the positions of supercoiled (SC), open circular (OC)
and linear (L) DNA. (b) A 35 nt synthetic ssDNA substrate with a fluorescent emitter at
the 5’ end and a quencher at 3’ end was incubated for 14 hours with increasing
amounts of each protein; fluorescence was measured as relative fluorescence units
(RFU).
Reprint from ref 47.
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The estimation of changes in free energies of association between UL98 AN and
ds DNA upon mutation using HINT (refer section 3.3.1.7) predicts that D, E or K è A
substitution mutants should lack both exo and endo activity and that R or S è A
mutants may have impaired exo activity. As no 5’ phosphate is present on the substrate
in endonucleolytic cleavage, endo activity might be unaffected in R or S è A mutants.
Consistent with this, we observed experimentally that the D, E or K è A mutants lacked
measureable exo activity. Endo activity was greatly reduced, but low-level activity was
still apparent with the supercoiled dsDNA substrate. Of the two UL98 mutations
targeting putative phosphate-binding residues, R164A behaved as predicted. Exo
activity was reduced by 90%, but there was no impact on endo activities detected with
supercoiled dsDNA or end blocked ssDNA substrates. In contrast, the S252A mutation
eliminated exo activity, and reduced both ssDNA and supercoiled dsDNA endo activities
to levels similar to those of the K280A mutant. We believe that the proximity of the S è
A mutation, one residue from the catalytic aspartic acid, may have perturbed the local
geometry of the active site enough to impair catalytic function, and hence to have
impacted not only exo but also endo activity.
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3.3.4 3D Virtual Screening Hits
We have performed a virtual screening study on the active site of UL98 AN for
possible identification of its novel inhibitors. The model of UL98 AN complexed to
dsDNA, validated by mutagenesis, identified important residues in the enzymes’ activesite. Based on the interactions of the 5’ phosphate group and the scissile
phosphodiester group in the active site of UL98 AN, it was clear that negatively charged
groups were desirable in the ligand. The model also helped predict other electronic and
structural features that would appear to be necessary for a molecule to bind at the
active site.
A pharmacophore model describing molecular features that are necessary for
recognition by the enzyme was generated. One of the important features in the active
site of the enzyme is the anionic site formed complementary to the side chains of R164
and S252, which accommodates the 5’ end phosphate group of DNA. This site was
defined as a “negative center” in the query. The second feature defined was a “donor
atom” feature in order to look for a hydrogen-bond donor group in the ligand, capable of
interacting with the carboxylate groups of D254 and E278. An “acceptor atom” was
defined in the vicinity of K280, with an aim at engaging the amino group that is
important for stabilizing the leaving group of substrate. The central hydrophobic
aromatic core was defined to impart rigidity to the molecule. A larger region was defined
so that compounds with bicyclic and tricyclic aromatic scaffolds can also be identified as
hits. Also, an aromatic scaffold affords synthetic ease during compound modifications at
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the stage of lead optimization. A distance constraint was set up between the two
features for better defining the 3D shape of the cavity and to eliminate many
undesirable compounds. Receptor site constraints were set up around the atoms
surrounding the cavity, in order to avoid steric clashes. The compounds VDW volume
must not intrude into these exclusion spheres to be considered a hit. The final threedimensional query is shown in Figure 3.12.
The compounds in NCI Open Database were screened against the
pharmacophore model using the “flex search” algorithm within UNITY. This algorithm
generates all possible conformations of a given candidate structure, performs
minimization in torsion angle space, and attempts to determine if it can reasonably flex
into a conformation that matches the query.67 The compounds were also checked
against the pre-defined set of rules, Lipinski’s Rule of Five (that gives a molecule
favorable permeation and absorption characteristics), viz. the molecule should have
less than 5 hydrogen-bond donors and 10 hydrogen-bond acceptors, its molecular
weight should be less than 500 D and its ClogP less than 5.
The process of virtual screening narrowed down the number of compounds from
~250,000 to a more manageable number of 72. All these ‘hits’ were docked into the
active site of UL98 AN, and the docked poses were rescored using HINT. The best
binding mode of each compound, based on HINT scores, was analyzed visually to
identify a reasonable binding in the active site such that the catalytically important
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Figure 3.12 – Pharmacophore Model.
Negative-center (radius 1 Å) showed as red sphere, donor-atom (radius 0.5 Å) showed
as cyan sphere, acceptor-atom (radius 0.5 Å) showed as red sphere, aromatic
hydrophobic center (radius 1.5 Å) showed as green sphere. Distance constraint (±0.5 Å)
set up between negative-center and acceptor-atom. Purple spheres are the receptorsite constraints.
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residues would be engaged. Table 3.3 / Figure 3.13 shows the list of top 15 chemically
diverse compounds identified as “hits”, along with their NSC numbers and HINT scores.
Figure 3.14 shows compound NSC 120634, which is the second best scored
compound, within the active site of UL98 AN. Even though NSC 238165 had a higher
score, NSC 120634 showed perfect fit into the pharmacophoric model, satisfying all the
features defined to be desirable in a candidate structure. Also, its binding mode predicts
interactions with all the catalytically important residues, D254, E278, K280, as well as
those involved in 5’-phosphate-binding, R164 and S252.
All compounds listed in Table 3.3 were obtained from the NCI and are currently
being evaluated for their exonuclease and endonuclease inhibitory activity. Suitable
candidates shall also be evaluated for their antiviral activity in cell culture and for toxicity.
Some of these compounds have HINT scores significantly higher than that of dsDNA in
the active site (refer Table 3.2), and hence might be expected to be stronger binders of
UL98 AN.
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Table 3.3 – Top 15 hits from virtual screening (ranked based on HINT scores)

	
  

Rank

NSC #

HINT Score

1

NSC 238165

9665

2

NSC 120634

8171

3

NSC 175852

6639

4

NSC 342023

6259

5

NSC 60279

5975

6

NSC 37413

5283

7

NSC 37053

5210

8

NSC 163

4670

9

NSC 226640

3943

10

NSC 132073

3582

11

NSC 163091

3510

12

NSC 44630

2900

13

NSC 129478

2880

14

NSC 329204

2747

15

NSC 41439

2656
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Figure 3.13 – Structures of virtual screening hits (top 15)
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NH2
S
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O
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OH

NSC 120634
5-(hydrazinylsulfonyl)isophthalic acid

Figure 3.14 – Binding mode of hit NSC120634.
The carboxylates of isophthalic aromatic nucleus shows strong salt-bridge interactions
with guanidine- and amino- groups of side chains of R164 and K280 respectively,
occupying positions analogous to the phosphate groups of DNA substrate. The
hydrazine moiety shows strong interactions with the carboxylate groups of D254 and
E278.
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3.4 Conclusion
In the absence of a crystallographic structure for UL98 AN, in silico modeling was
used to successfully build a structural model of the protein that predicted the residues
important for its nucleolytic functions. The predicted active-site residues – R164, S252,
D254, E278 and K280, were validated by mutagenesis, where alanine scanning showed
abolition of activity. Identification of residues involved in 5’-phosphate binding that affect
the exo, but not the endo activity, may provide a useful tool for exploring the biological
roles of each activity in herpesvirus replication.
The structural model provided a basis for performing rational drug discovery to
identify novel antiviral agents for CMV infections. A virtual screening for active site
inhibitors of UL98 AN was conducted on a pharmacophore, built based on our model,
followed by molecular docking and HINT scoring. We have identified a number of novel
scaffolds that have shown promise in our computational studies. These candidates are
currently being evaluated experimentally.
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CHAPTER 4
INCLUSION OF “RELEVANT” INTERFACIAL WATERS IMPROVE PROTEINPROTEIN DOCKING PREDICTIONS

4.1 Introduction

4.1.1 Protein-Protein Interactions: Need for Computational Prediction Tools
Protein-protein interactions play a fundamental role in most biological events and
many pathological processes. Virtually every molecular process in a cell is carried out
via interactions between two macromolecules; for example, DNA synthesis, gene
expression, post-translational modifications, transport, signal transduction, etc. Various
genetic, biochemical, or bioinformatics studies have identified tens of thousands of
proteins interacting with each other forming millions of putative complexes. A detailed
atomic understanding of the nature of these often-transient interactions is a key step to
exploiting/inhibiting these biomolecular associations as potential new routes to disease
therapeutics.
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A large number of datasets exist that contain experimentally verified proteinprotein interactions, like HPRD (Human Protein Reference Database),1 BIND
(Biomolecular

Interaction

Network

Database),2

MINT

(Molecular

Interactions

Database),3 etc. These databases contain a total of about 26,500 binary protein-protein
interactions,4 and provide a wealth of information pertaining to the human proteome.
These data are related to thousands of protein-protein interactions, post-translational
modifications, enzyme/substrate relationships, disease associations and more.
In contrast, the RCSB Protein Data Bank (http://www.rcsb.org/pdb/) only contains
a few hundred protein-protein complex structures. One of the reasons for this lack of
structural information is that experimental structural determinations using techniques
like X-ray crystallography, Nuclear Magnetic Resonance (NMR) and Electron
Microscopy (EM) are very demanding.5
During the past couple of decades, there has been a rapid emergence of novel
computational algorithms to predict, model and understand these interactions – also
known as protein-protein docking methods. These predictive methods have been very
essential for progress, since the experimental structural determination techniques,
although powerful, definitely have low throughput. Accurate and reliable computational
predictions are very useful in inferring how two proteins bind, give valuable functional
information about the interacting proteins and also help guide new genetic and
biochemical experiments.

A number of docking algorithms and different scoring

functions have been developed in recent times, and this endeavor has gained wide
popularity as seen by the CAPRI (Critical Assessment of PRedicted Interactions), a
communitywide experiment.6 Wodak and Janin were the first to develop a predictive
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algorithm, in the late 1970s that generated possible orientations of one protein relative
to another.7

4.1.2 Protein-Protein Docking: The Process
As the field developed, protein-protein docking algorithms have become more
sophisticated partly due to the rapid progress in computer hardware, but also due to our
improved understanding of structure and interactions. The docking protocols have
evolved from simple rigid-body docking (where both interacting partners are considered
as rigid solid bodies), to soft-body docking (which incorporates side-chain and backbone
flexibility in either one or both molecules), to inclusion of short MD simulations (to obtain
an induced-fit model), to inclusion of explicit solvent models within their docking
protocols; all of which are probably directly attributed to the availability of increased
computational power.
The process of docking macromolecules is multi-step, involving accurate
representation of the system, conformational space search, protein flexibility upon
association and ranking of potential solutions.8
In most of the current docking approaches, the description of the protein surface
is the atomic representation of its solvent-exposed residues, using mathematical models
such as geometric shape descriptors like the Connolly surface.9 The geometric
descriptors that accurately represent the maxima (holes) and the minima (knobs) of the
shape function10,11 are usually combined with other computed properties designed to
have physicochemical meaning like the affinity grids that are calculated based on the
force field potentials for Van der Waals and electrostatic interactions.12 Precise
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representation of the system is followed by a search of the available conformational
space. The majority of programs employ an “ab-inito” approach: one of the docking
partners (usually the larger one) is fixed in space and the second protein is rotated and
translated around the fixed one. Different search methods have been used: matching
surface complementarity at the protein-protein interface;13 combining geometric
complementarity with amino acid pairwise affinities at the interface;14 Fourier correlation
techniques such as the FFT algorithm, first described by Katchalski-Katzir et al.,15 which
evaluates the interface contacts between binding partners while penalizing protrusions
into the protein core. Other algorithms like geometric hashing,10,16-18 Genetic
algorithms,19 Brownian dynamics simulations,20 and simulations combined with energy
minimization21 have also been applied to the docking problem.
The induced fit model suggested by Koshland shows that conformational
changes could occur upon binding.22 A variety of studies followed that supported this
theory of flexibility. It is impractical to treat molecular flexibility in an explicit way in the
case of protein-protein docking, due to the large number of atoms and degrees of
conformational freedom involved. However, a number of approaches have tried to
address this shortcoming. A recent review by Andrusier, et al. describes how protein
flexibility is treated during different stages of the docking process.23 Some docking
protocols adopt a two-stage approach that combines rigid-body search with molecular
dynamics to account for backbone and/or side-chain flexibility. Side-chain optimization
has been shown to discriminate near-native conformations from false positives.24
Another algorithm, SOFTSPOTS identifies interfacial residues most likely to undergo
conformational change at an interface, and generates the corresponding rotamers,
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before the docking calculations.25 Incorporating full backbone flexibility is highly
challenging, because too large a conformational change in a backbone may lead to
deformation of global structure. Various docking methods handle backbone flexibility
differently – some methods utilize “soft docking” protocols that initially allow steric
clashes, followed by a refinement step; some perform ensemble docking, using different
conformations generated a priori; some methods deal with hinge-bending motions, while
other methods perform a wide conformational space search to identify energetically the
most favorable one.23
Comprehensive search algorithms generate a huge number of potential solutions,
from which the one corresponding to the lowest free energy of binding must be found.
An ideal scoring function should be able to distinguish between native-like predictions
from false-positives. During the complex prediction step, the degree of shape
complementarity of the interacting protein surfaces is used as an initial filter to eliminate
incorrect predictions; but that alone is not sufficient to take into account the complete
energetics of protein-protein associations. In most of the algorithms developed so far
the initial filtering is then followed by ranking the predicted solutions using scoring
functions that take into account geometric complementarity, electrostatic interactions,
hydrogen bonding and/or desolvation energy.26-28 Most scoring functions are designed
to predict the free energy of binding ΔGbinding, which is not a trivial task, since the
individual components within them are imperfectly able to completely characterize the
biomacromolecular association process.12 Despite efforts to identify the correct binding
modes using free energy as a reliable guide, scoring still remains a major challenge in
the docking process.
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4.1.3 Current Protein-Protein Docking Algorithms
With the emergence of novel docking approaches to predict biomacromolecular
associations, a community-wide experiment to evaluate their capabilities was designed
– called CAPRI (Critical Assessment of PRedicted Interactions).6 CAPRI is a datadriven blind experiment wherein participating groups submit predictions of a target
complex using their docking algorithms. The experiments would start when an
unpublished X-ray crystal structure or NMR structure of target protein-protein or proteinDNA complex is made available by experimentalists to the CAPRI management. The
atomic coordinates of the interacting partners are provided to participating structural
biologists, who within 4-6 weeks, submit a set of 10 models that are compared to the
experimental structure. The quality of the submitted models is evaluated based on the
standard CAPRI criteria (that will be discussed in detail in Section 4.2.4) and classified
as models of “high”, “medium” and “acceptable” accuracy.29
The most recently concluded 4th CAPRI Evaluation Meeting held at Mare
Nostrum, Barcelona (2009) evaluated rounds 13-19 that took place over a period of
2007-2009 and comprised a total of 14 targets. 76 participating groups submitted a total
of 4420 docking predictions.30 Rounds 1-2 of CAPRI with a total of 7 targets were
evaluated in 2002, rounds 3-5 with a total of 10 targets were evaluated in 2005, and
rounds 6-12 with a total of 9 targets were evaluated in 2007.6,29,31 Each evaluation
round has been well reported in special issues of the journal Proteins: Structure,
Function and Bioinformatics (Proteins 2003:52; Proteins 2005:60 and Proteins 2007:69).
The comparison of various docking programs based on their relative
performance in the CAPRI experiments over the last decade is very difficult since the
	
  

121

algorithms differ in the methods used to perform the conformational search and score
the predictions, and may perform better for different types of targets. A recent review on
protein-protein docking by Moreira, I. S. et al.12 analyzed the performance of the
participants by giving quantitative measures to the quality of submitted models for each
target.
Globally, ICM-DISCO,32 ZDOCK,28 HADDOCK33,34 and RosettaDock27 have been
the best predictors over the past decade. The same review article also compares the
popularity of these programs based on the citations per year, which suggests that the
most popular ones are HADDOCK,33,34 RosettaDock,27 ClusPro35 followed by
PatchDock36 and ZDOCK.28 Table 4.1 summarizes the software characteristics, along
with some advantages and disadvantages, of the top 5 programs (based on their
performance in the CAPRI experiments and software popularity).

4.1.4 Solvated Docking
Water is a vital component in all living organisms and plays a crucial role in all
biological processes. Particularly for proteins, the dynamics of water-protein interactions
govern various molecular phenomena – like protein folding and molecular recognition,37
as well as maintenance of structural integrity.38 A water molecule can act both as a
donor and as an acceptor of hydrogens, capable of forming four directional hydrogen
bonds. This allows for easy and rapid reorientation and reconfiguration into different
three-dimensional structures. Due to this unique property of water, the strongly bound or
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Table 4.1 – Protein-Protein Docking Softwares: Characteristics, advantages and disadvantages (adapted from ref 12)
Software

	
  

Conformational Search
Algorithm

Filtering at search
stage

Flexibility
Search stage
Refinement stage

ICM - DISCO
(Docking and
Interface Side-Chain
Optimization)

Rigid Body Docking; pseudoBrownian Monte Carlo
minimization

Specific filtering criterion
on a case-by-case basis

–

Fully-flexible
interface ligand sidechains

ZDOCK

Rigid body search using Fast
Fourier Transform (FFT)
algorithm

Biological data drivendocking. Allows definition
of interfacial and blocking
residues

–

Optimizes full atoms
internal energy and
vdW

HADDOCK
(High Ambiguity
Driven protein-protein
DOCKing)

Three stage process - (i)
randomization of orientations
and rigid-body energy
minimization (EM), (ii) semirigid simulated annealing in
torsion angle space (TAD-SA),
(iii) refinement in Cartesian
space with explicit solvent

Data driven docking Use of chemical shift
perturbation data and
NOEs/RDCs data from
NMR experiments

RosettaDock

Rigid-body Monte Carlo
search followed by
minimizations

ClusPro

Rigid body search using Fast
Fourier Transform (FFT)
algorithm

–

Filtering using empirical
free energy functions
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Interfacial
side-chain
flexibility

Side-chain and
backbone flexibility
in the simulated
annealing and
minimization stages

Side chain
minimizations

–

–

–

Table 4.1 – Protein-Protein Docking Softwares: Characteristics, advantages and disadvantages (cont.)
Software

	
  

Advantages

Scoring
Search stage

Refinement stage

ICM - DISCO
(Docking and
Interface Side-Chain
Optimization)

Truncated vdW potential,
Electrostatic potential
corrected for solvation,
hydrogen-bonding
potential, hydrophobicity
potential

Truncated vdW potential,
Electrostatic potential
corrected for solvation,
hydrogen-bonding potential,
hydrophobicity potential,
rotamer probability

Global procedure, fullyautomated, handles
induced changes of
interface side-chains

ZDOCK

Pairwise shape
complementarity (PSC)

PSC, desolvation and
electrostatics

Performed effectively for
antibody-antigen test
cases in CAPRI
experiments

HADDOCK
(High Ambiguity
Driven protein-protein
DOCKing)

Clustering, based on
intermolecular energies

Average interaction energies
(Sum of electrostatic
potential, vdW potential,
ambiguous interaction
restraints AIR derived from
experimental information
available) and Average
buried surface area

Side chain and backbone
flexibility, use of
experimental data
restraints narrows the
space search to relevant
regions

RosettaDock

Residue-residue
interaction potential

van der Waal's potential,
desolvation potential,
hydrogen-bond potential,
electrostatics

Protocol mimics the
physical process of
docking, with refinement
stage optimizing the
interfacial side-chain
packing

ClusPro

Shape complementarity,
desolvation and
electrostatics

Shape complementarity,
desolvation and
electrostatics

Fully-automated program,
performs docking, filtering
and scoring rapidly
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Table 4.1 – Protein-Protein Docking Softwares: Characteristics, advantages and disadvantages (cont.)
Software

	
  

Disadvantages

Web address

References

http://www.molsoft.com/docking.html

32

ICM - DISCO
(Docking and
Interface Side-Chain
Optimization)

Less successful for
cases with significant
backbone
rearrangements

ZDOCK

Ineffective for cases
with large
conformational change

http://zlab.bu.edu/zlab/index.shtml

28

HADDOCK
(High Ambiguity
Driven protein-protein
DOCKing)

(i) Ineffective in cases
without additional
experimental data, (ii)
highly dependent on
accuracy of biological
information available a
priori

http://www.nmr.chem.uu.nl/haddock/

33, 34

RosettaDock

Less successful for
cases with significant
backbone
rearrangements

http://graylab.jhu.edu/docking/rosetta/

27

ClusPro

Cannot introduce
additional information to
drive correct docking

http://cluspro.bu.edu/home.php

35
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“conserved” waters (those that are consistently observed in several crystallographic
structures and not easily displaced by ligands) are capable of modifying the protein
surface properties like its shape and charge.
Even though Bogan and Thorn (1998) proposed an O-ring hypothesis for
interfaces claiming that occlusion of solvent by hot spot residues is found to be a
necessary condition for energetically favorable interactions,39 the abundant presence of
water at protein-protein and protein-DNA interfaces underscores the vital role played by
water in the polar interactions that stabilize the complexes.40 Jannin’s closer
examination of structural data on protein-protein and protein-DNA recognition sites
revealed that the associated interfaces contain at least as many water-mediated
interactions as direct hydrogen bonds or salt bridges.40
Some research groups have made efforts to incorporate water-molecules in
protein-ligand docking protocols, both explicitly and implicitly. The very first hurdle in this
effort is the determination of bound water molecules at the ligand binding site. Several
methods available for identifying/predicting protein-ligand interfacial waters have shown
promise. GRID41 performs well in predicting ligand-binding site water molecules, by
calculating interaction energy using Lennard-Jones potential, electrostatic and
hydrogen-bond terms. AQUARIUS,42 a knowledge-based approach, identifies water
sites in proteins from the experimentally generated electron density maps. CS-Map
predicts the most favorable binding position of water molecules on protein surface
based on an interaction potential that accounts for van der Waals, electrostatic and
solvation contributions.43 The Fold-X force field allows the prediction of positions of
bound water molecules that show interaction with two or more polar atoms of proteins.44
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A more recently available tool WaterMap,45,46 predicts active-site bound water
molecules by solvating the site and calculating its thermodynamic properties. A few
protein-ligand docking programs like Flex-X,47 Autodock,48 GOLD,49 and GLIDE50,51
have shown significant improvements in docking performances by developing
algorithms to include contributions from interfacial waters.52
All these approaches have shown a lot of promise in protein-ligand systems;
however, water has been neglected in almost all protein-protein docking algorithms.
Most of the development in solvated protein-protein docking has been focused on
implicit treatment of solvent molecules, as it reduces the computational cost associated
with explicit treatment. Chen et al.53 have reviewed the progress from in-vacuo to insolution docking, using implicit solvent-based methods. Although promising, a more
detailed understanding of a protein-protein complex interface can perhaps be achieved
from explicit treatment of water molecules. HADDOCK is one of the few docking
programs designed to account for explicitly added water molecules in the docking
process. Its solvated docking protocol starts with hydrating individual protein molecules,
followed by rigid-body docking process resulting in a water layer in between the two
proteins. All non-interfacial water molecules are then removed and a fraction of resulting
interfacial waters is subsequently removed in a biased Monte Carlo procedure based on
water-mediated contact probabilities. This methodology resulted in noticeable
improvements both in quality and scoring than unsolvated docking, for most of the 10
studied cases that included examples of both wet and dry interfaces.54
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4.1.5 Explicit Hydropathic Approach
Our lab, led by G. E. Kellogg, along with our collaborators have been interested
in understanding the energetic contribution of water molecules in various biological
environments. The empirically derived HINT forcefield (described in detail in Section
1.5), which models both hydrophobic and polar non-covalent interactions between two
molecules, forms the basis for our analyses.
In a study on five β37 mutant hemoglobin crystal structures, Burnett et al.
showed the contribution of crystallographically important water molecules in the dimertetramer assembly.55 Fornabaio et al. developed an approach based on HINT energy
function to map the energetics of water-protein and water-ligand interactions at proteinligand interfaces. They analyzed the protein-ligand interactions in the active site of 23
HIV-1 protease-ligand complexes and showed significant improvement in correlation
between HINT scores and experimentally determined binding constants when
appropriate bridging water molecules are taken into account.56
In another study by Amadasi et al., protein-water and water-ligand interactions in
the binding site of sets of uncomplexed and ligand-complexed proteins were evaluated
using the HINT forcefield.57 Also, each water molecule was scored using the Rank
algorithm,58 which assigns a higher rank to a water molecule that is capable of a
maximum of four hydrogen-bonds (≤2 donors and ≤2 acceptors). The HINT free energy
scoring model and the Rank algorithm were combined to develop a statistically
validated Water Relevance Metric59 that classifies water molecules in protein binding
sites that are generally conserved (between unliganded and ligand-bound states) as
“Relevant” waters. These high Relevance waters are not likely to be displaced by the
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ligand and should be explicitly considered when building geometrically and functionally
correct models of the binding site. This also has implications in structure-based drug
design, as it helps to identify key polar interactions within a protein’s binding site that
can be utilized to design more potent ligands with polar functional groups capable of
mimicking water’s hydrogen bonds.
Spyrakis et al. calculated HINT interaction scores for 39 crystallographic proteinDNA complexes, taking into account the contributions from interfacial waters that act as
linkers between amino acid side-chains and nucleotide bases. The study quantified the
key energetic role of bridging waters in protein-DNA associations.60 Recently, Ahmed et
al. performed a comprehensive study on the role of bound water at protein-protein
interfaces.61 Analysis of a total of 4741 water molecules at the interface of 179
heterodimeric protein-protein complex crystal structures revealed that 21% of the bound
water is involved in bridging interactions with both proteins. Their analysis also showed
that the total energetic contribution of bridging water ranges up to -11.35 kcal mol-1 per
protein pair. Another, more subtle, role that these bridging waters serve at the interface
is act as nano-scale pH buffers owing to their ability to easily swap between acting as
hydrogen-bond donors and acceptors and thus maintain the integrity of the interface.
This comprehensive study emphasized the importance of characterizing the behavior of
biological waters as their presence at the interface may influence the assembly of
biomacromolecular complexes, and begins to establish a basis for including the effects
of individual waters in macromolecular docking algorithms.
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4.1.6 Specific Aims
Protein-protein interactions involved in various biological pathways can be
exploited as novel targets for rational drug discovery. A detailed atomic level
understanding of interactions at protein-protein interfaces is crucial to identify hot-spot
residues guiding their recognition. In the absence of experimentally determined 3D
structure of a protein complex, a docking algorithm aims at predicting it starting from
atomic resolution structures of the individual components. Although the challenges
remain significant, different tools for protein-protein docking have been reasonably
successful at modeling biomolecular associations, as seen from the recent CAPRI
evaluation.30 Overall, 67% of the participating groups produced acceptable models for at
least one target. No evident correlation was seen between the ranks of models and their
accuracy,62 underscoring again the weakness of current scoring function methodology.
Several studies in our lab, including Chapter 2 and Chapter 3 of this work, have
successfully shown the utility of the HINT paradigm in calculations of free-energy of
binding for protein-ligand complexes56,63,64 as well as protein-DNA complexes.65 The
Computational Titration (CT) algorithm, based on HINT force field, is capable of
exploring the protonation states of protein active site residues and ligand functional
groups.66,67 The Water Relevance metric59 has been shown to accurately (92% in cases
with ≤2.0 Å resolution) predict the conserved water molecules at protein-ligand
interfaces based on only the unliganded protein structure. It is our current long-range
goal to incorporate HINT force field along with these tools into a protein-protein docking
algorithm. While the process of docking is principally a two-stage search and score
problem, the HINT-based tools can initially be applied easily in the latter stage of
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complex refinement and scoring. We believe that a protein-protein docking algorithm
accounting for not only the physical effects of biomolecular association like shape
complementarity and residue flexibility, but also the associated chemical effects like
hydropathic complementarity, correct residue ionization states and explicit inclusion of
interfacial water molecules will yield more realistic models, but these effects must be
incorporated during the search stage and will be reported in other reports from our
laboratory. The current work addresses the issue of explicit solvent accounting during a
protein-protein docking process.
In this study, we investigate the effect of bridging waters on docking performance.
ZDOCK, a rigid-body protein-protein docking program, was used for the purpose of this
study, as it has consistently been a top performer at the CAPRI experiments.12 The
main aim of this project was to check the influence of explicit water accounting on the
accuracy of predictions, and not necessarily to improve upon the current ZDOCK
algorithm. Interfacial waters relevant to both interacting partners were identified using
the HINT Relevance metric. We forced ZDOCK to include these waters as atoms in one
of the two interacting proteins, and show that more accurate results are obtained when
water is not ignored.
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4.2 Methods

4.2.1 Data Set
A non-redundant benchmark for protein-protein docking algorithms, which
contains test cases for which the 3D structures of the complex and both unbound
components are available, was developed by Weng’s group at University of
Massachusetts.68 To obtain a set of well-structured interfacial waters, the data set for
this study was limited to those cases for which the bound complex resolution is ≤ 2.0 Å.
The coordinates for all the complexes in our data set were obtained from the
Protein Data Bank (http://www.pdb.org/). First, all ligands and cofactors were deleted
from each complex structure using SYBYL v8.1 (TRIPOS, Inc.). For cases with “multi”mer assembly, only one chain of each component forming the complex was retained.
Hydrogen atoms were added and minimized under the Tripos force field (1000 iterations,
0.01 kcal mol-1 Å-1 gradient, Gasteiger-Hückel charges), keeping the coordinates of all
heavy-atoms fixed. Interfacial waters, those that are within 4 Å from atoms on both
interacting proteins, were retained with each protein-protein complex. For each test
case, the larger protein of the two was defined as the “receptor” protein, which would be
kept fixed during the docking process, and the smaller one as the “ligand” protein.

4.2.2 Determination of “Bridging” Interfacial Waters –
Intermolecular interaction score was calculated between each receptor-ligand
pair using HINT scoring function.69 In principle, the HINT model scores each atom-atom
interaction (𝑏!" ) between atoms i and j using –
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𝑯𝑻𝑶𝑻𝑨𝑳 =    𝚺𝒊 𝚺𝒋 𝒃𝒊𝒋 =    𝚺𝒊 𝚺𝒋 𝒂𝒊 𝑺𝒊 𝒂𝒋 𝑺𝒋 𝑻𝒊𝒋 𝑹𝒊𝒋 +    𝒓𝒊𝒋

(1)

where, a is the hydrophobic atom constant, S is the solvent accessible surface area, Tij
is a logic function assuming +1 or -1 value depending on the character of the interacting
polar atoms, and the distance dependent functions Rij and rij are simple exponential
function e-r and an implementation of the Lennard-Jones potential function,70,71
respectively. A direct HINT interaction score was calculated for every protein-protein
complex, without accounting for the contributions made by interfacial waters. The HINT
parameters and controls used were similar to those in the previous studies57,60,65 – the
protein molecules were partitioned using the dictionary method, with essential hydrogen
treatment (where polar hydrogens are treated explicitly and non-polar ones are treated
implicitly), and a 30 Å2 correction used for calculations of the S-values for backbone
amide nitrogens.
Next, the crystallographic orientation of every water molecule at the interface was
optimized using an algorithm that performs an exhaustive search of its orientation space
to assign H-atom positions.72 This algorithm, developed around the HINT empirical force
field, treats every water molecule as a ‘small-ligand’ and the surrounding atoms (within
6-8 Å) from both proteins as its ‘binding-site’. HINT scores are calculated between the
water molecule and its surroundings, allowing rotation of H-atoms around the three axes
and limited translation of O-atom centroid with an aim at maximizing the interaction
score.
The Rank algorithm72 was applied to the optimized water molecules. Ideally, a
water molecule is capable of forming a maximum of four hydrogen-bonds (≤2 donors
and ≤2 acceptors) with its surrounding atoms. Rank represents the weighed number of
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potential hydrogen bonds that each optimized water molecule forms, and is calculated
as shown
𝑹𝒂𝒏𝒌 = 𝚺𝒏 𝟐. 𝟖𝟎  Å/𝒓𝒏 + 𝚺𝒎   𝒄𝒐𝒔 𝜽𝑻𝒅 −    𝜽𝒏𝒎 /𝟔   

(2)

where, rn is the distance between the water O-atom and target heavy atom atom n (n =
1 to number of valid targets), θTd is the ideal tetrahedral angle (109.5°) and θnm is the
angle between targets n and m (n = m to number of valid targets). The Rank algorithm
yields values ranging from 0 for waters that do not form any hydrogen bonds with nonwater molecules to about 6 for waters forming four high quality hydrogen bonds with
excellent bond length and bond angle geometry.
In order to classify the water molecules, its HINT score and Rank were combined
to give a Relevance value.59 The Relevance of a water molecule is calculated using the
weighed probability equation –
  𝑷𝑨 =   

𝑷𝑹 𝑾𝑹 + 𝟏 𝟐   +    𝑷𝑯 𝑾𝑯 + 𝟏
𝑾𝑹 + 𝟏 𝟐   + 𝑾𝑯 + 𝟏 𝟐  

𝟐  

(3)

where, PA is the overall probability or the “Relevance” value for a water molecule, PR
and PH are the percent probabilities for water conservation based on Rank and HINT
score, and WR and WH are the weights for these probabilities, respectively. A water
molecule at a protein interface with PA ≥ 50% is considered “conserved” water, meaning
it would be present in ligand-bound complex. This water Relevance metric, although
trained on protein-ligand complexes, was extended to protein-protein complexes in
order to identify the waters contributing towards bridging interaction, as we showed
earlier.61
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The Relevance value for interfacial waters in all test cases was calculated using
the above described model. We propose that an interfacial water molecule that is
involved in bridging interactions should be Relevant to both proteins. As previously
used,61 our criteria for considering a water molecule to be “truly bridging” was a
Relevance score of ≥ 0.25 with respect to both proteins (thus giving it a total value of ≥
0.5). With this definition, the HINT scores, Rank and Relevance scores for interfacial
waters in every test case was calculated.

4.2.3 Solvated Docking using ZDOCK –
For the present study, ZDOCK v3.0.2 (that incorporates a 3D convolution library
to improve its efficiency) was obtained from http://zdock.umassmed.edu/software/. A
total of 100 solutions were generated for each receptor-ligand pair in the data set. Since
bound-bound docking was performed, a seed integer was specified for randomization of
the starting coordinates for ligand structures. Also, rotational sampling was set to dense,
which means the rotational search was performed in 6° steps. The receptor protein
coordinates were fixed, preventing its rotation or switching with ligand during execution.
Using these parameters, two different docking protocols were evaluated on every
case in the data-set of 15 protein-protein complexes:
1. Unsolvated Docking: Standard rigid-body docking, absence of interfacial
water molecules.
2. Solvated Docking: Rigid-body docking, explicit inclusion of “bridging” water
molecules identified using the HINT-based water Relevance metric.
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For solvated docking, the interfacial bridging water molecules identified were added to
the receptor file, and considered as a part of the protein. Since the ZDOCK
program is not parameterized to include explicit waters in its algorithm, the ACE type,
atom radius and atom charge for each water molecule was manually updated in the
input file.
The ZDOCK output file provides information regarding the rotation and
translation for the ligand with respect to its initial positioning. The protein-protein
complex file was generated for each prediction; hydrogens were added and subjected to
minimization under the Tripos force field (1000 iterations, 0.01 kcal mol-1 Å-1 gradient,
Gasteiger-Hückel charges).
HINT interaction scores for unsolvated docking were calculated between the
receptor protein and ligand protein for each prediction. In the case of solvated docking,
the water molecules at the interface were first optimized using the water-optimization
algorithm, as described earlier, followed by the HINT interaction score calculation that
accounts for contributions from interfacial waters. For the purpose of comparison, the
HINT scores were normalized with respect to the top HINT score for each case. The
HINT scores for each prediction were represented as a fraction of top HINT score for
each individual test case. The predictions were then ranked based on their scaled HINT
scores.

4.2.4 The Assessment Protocol –
A standard CAPRI assessment criteria was used to evaluate the predictions
against the target crystallographic structures.29 A number of different characteristics of
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predicted complexes were evaluated – not just the root mean square deviations
(interfacial and ligand), but also the identification of correct residue-residue contact pairs,
which is extremely important for inhibitor design. Figure 4.1 and 4.2 shows the
schematic illustration of the three different parameters used to assess the quality of the
predictions.
Residue-Residue Contact Pairs (fnat) – Residues on either protein at the interface were
considered to be in contact if any of their atoms were within 5 Å of each other. The total
number of residue-residue contact pairs was calculated for the target structure
(crystallographic complex structure) and for each prediction using SYBYL v8.1. ‘fnat’,
defined as the fraction of number of native/correct contacts identified in the predicted
complex structure with respect to the target structure, was then computed.
Ligand Root Mean Square Deviation (l-RMSD) and Interface Root Mean Square
Deviation (i-RMSD) – Two more parameters were calculated to evaluate the 3D fit
between the predicted complexes and target structures. The global geometric fit was
calculated by computing the l-RMSD, which is defined as the RMSD of the ligand
backbone atoms in the predicted complexes versus the target structure, after
superimposing the receptor protein. The fit within the interfacial region was quantified by
calculating the i-RMSD, defined as the RMSD of the backbone atoms of all interfacial
residues of predicted complexes versus target structure. For this calculation, interfacial
residues were defined as those within 10 Å of the partner molecule. The interfacial
residues were identified using SYBYL v8.1 and the l-RMSD and i-RMSD calculations
were performed using the McLachlan algorithm73 as implemented in the program ProFit
(Martin, A. C. R. and Porter, C. T., http://www.bioinf.org.uk/software/profit/).
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The predictions were classified into four categories – incorrect models, acceptable
models (*), medium-accuracy models (**) and high-quality models (***) based on the
acceptance criteria shown in Table 4.3.
Average Hit Count – A prediction with medium-accuracy or better (** or ***) was
considered a “hit”. An average hit count was calculated for the top N predictions for both
unsolvated and solvated docking protocols.
Weighted Score – For the purpose of giving quantitative measures to the success of the
two docking protocols, a weighted-scored was calculated for each test case by giving a
value of 0, 1, 2, or 3 to the incorrect, acceptable, medium and high accuracy predictions
within top N models ranked based on HINT scores, respectively.
Statistical Analysis – All the statistical analysis were performed at the level of
significance α = 0.05 using the software JMP v10.74
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Figure 4.1 – Schematic illustration of residue-residue contact pairs. A receptor residue
is considered to be in contact with a ligand residue if any of its atoms were within 5 Å of
each other. fnat is the fraction of native/correct residue-residue contact pairs identified
in a prediction.

Figure 4.2 – Schematic illustration of ligand and interface RMSDs. l-RMSD is the
RMSD of ligand backbone atoms between prediction and target structure, after
superimposing receptor atoms. i-RMSD is the RMSD of interfacial residues, those within
10 Å of partner molecule.
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Table 4.2 – Predicted model quality classification criteria29

Model Quality
Incorrect

Criteria
fnat < 0.1 OR (l-RMSD > 10.0 Å AND i-RMSD > 4.0 Å)

Acceptable (*) (fnat ≥ 0.1 AND fnat < 0.3) AND (l-RMSD ≤ 10.0 Å OR i-RMSD ≤ 4.0 Å)
OR
fnat ≥ 0.3 AND l-RMSD > 5.0 Å AND i-RMSD > 2.0 Å
Medium (**)

(fnat ≥ 0.3 AND fnat < 0.5) AND (l-RMSD ≤ 5.0 Å OR i-RMSD ≤ 2.0 Å)
OR
fnat ≥ 0.5 AND l-RMSD > 1.0 Å AND i-RMSD > 1.0 Å

High (***)

	
  

fnat ≥ 0.5 AND (l-RMSD ≤ 1.0 Å OR i-RMSD ≤ 1.0 Å)
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4.3 Results

4.3.1 Data Set
The protein-protein docking benchmark, developed by Weng’s group,68
comprises a total of 176 cases that are classified into three classes based on the extent
of conformational change at the interface upon complex formation – rigid body cases
(123), medium difficulty cases (29) and difficult cases (24). The high-resolution (< 2.0 Å)
subset of 42 complexes chosen from the data set contains cases from all the three
classes defined by Weng and also represents a good sampling of the protein interface
sizes,75 with change in accessible surface areas (ΔASA) on complex formation ranging
from 808 to 3347 Å2.68 A complete hydropathic analysis of the protein-protein interface
for each test case was performed using HINT. Only those water molecules that were
relevant to both proteins, the so-called “Relevance 2” waters or “Bridging” waters, were
retained with their protein-protein complexes, while those that were relevant to just one
protein or neither were ignored for the present study. 12 out of 42 cases did not show
the presence of any bridging waters and were removed from the data set. HINT
interaction scores were now calculated, using the same parameters as described before,
now taking into account the contribution of bridging waters. Table 4.2 lists the set of
randomly selected 15 protein-protein complexes used for this study, along with their
PDB ID, crystallographic resolution, chain IDs of receptor protein and ligand protein, the
total numbers of interfacial waters and relevance-2/bridging waters, and their HINT
interaction scores calculated with and without accounting for bridging waters.
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Table 4.3 – Solvated protein-protein docking data set

#

	
  

PDB ID

Resolution

Water

Chain ID
Rec/Lig

Interfacial

HINT Score

Bridging
HOH

Without HOH

Accounting for
Bridging HOH

1

1avx

1.90

A/B

8

2

2122.30

2364.61

2

1clv

2.00

A/I

30

8

-167.35

2319.10

3

1dqj

2.00

AB/C

17

7

1786.58

2863.55

4

1fle

1.90

E/I

12

1

1063.10

1035.44

5

1iqd

2.00

AB/C

25

6

2011.56

2589.28

6

1jiw

1.74

P/I

29

3

-2855.97

-1540.40

7

1jps

1.85

HL/T

8

3

1172.06

1458.27

8

1klu

1.93

AB/D

8

3

1249.55

1585.62

9

1pxv

1.80

A/C

24

5

450.66

2509.35

10

1r0r

1.10

E/I

27

6

-1361.36

-496.70

11

1r8s

1.46

E/A

24

5

118.12

1974.93

12

1wej

1.80

HL/F

10

6

1847.78

2735.49

13

1zhh

1.94

A/B

32

10

-411.06

2223.41

14

2hqs

1.50

A/H

46

7

-420.71

1523.90

15

2sic

1.80

E/I

17

1

-1.08

159.11
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4.3.2 ZDOCK – A rigid body docking program
ZDOCK uses the Fast Fourier Transform (FFT) algorithm to find the 3D structure
of a protein complex, starting from structures of individual components, by optimizing
three parameters – shape complementarity, electrostatics and desolvation free
energy.76 Each individual protein file is first parsed through the mark_sur program that
calculates the amount of accessible surface area (ASA) of each atom using a water
probe and marks the atom type based on its atomic contact energy (ACE).77 This is
followed by a search in the 3D translational space using a FFT approach with the ligand
protein, the smaller of the two, rotated in either 15° or 6° steps resulting in a total of
3,600 or 54,000 angles, respectively. The top scoring translation is retained for each
angle. Each receptor-ligand complex is scored using physical and biochemical
properties: i) pair-wise shape complementarity (PSC) that is composed of a favorable
term coming from number of atoms pairs between receptor and ligand protein within a
cutoff distance and a penalty term for number of overlapping grid points; ii) an
electrostatic energy term that correlates the electric potential generated by receptor with
the charges of ligand; and iii) desolvation free energy term calculated based on atomic
contact energies.76

4.3.3 HINT scores predict correct geometry
As previously mentioned, HINT scores have been successfully correlated to the
free energy of interaction in case of protein-ligand systems. The use of HINT scoring
function in distinguishing active molecules from inactive ones is well documented. The
first key question that must be answered before building protein-protein docking
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algorithms based on HINT scoring is whether that function accurately predicts geometry.
To test this, we performed a rigid-body docking on the data set of 15 high-resolution
protein-protein complexes (crystallographic resolution ≤ 2.0 Å). The coordinates of the
individual partners were obtained from the complex structure, and 100 predictions for
each test case were generated using ZDOCK (the unsolvated protocol). Intermolecular
interaction score for each prediction was calculated using the HINT, followed by ranking
them based on their scaled HINT scores. The accuracy of each prediction was
evaluated using the standard CAPRI criteria by calculating three parameters – the fnat
value, the l-RMSD and i-RMSD. Predictions were classified as incorrect, acceptableaccuracy, medium-accuracy and high-accuracy models according to the cut-offs
described in Table 4.3.
A prediction with high fnat value (close to 1) indicates correct identification of the
interface. Figure 4.3 shows a plot of fnat values vs scaled HINT score for all predictions
(n = 1500). A significant positive linear correlation was observed between the scaled
HINT scores and fnat values (r = 0.307, p < 0.0001). That is, predictions with high
scaled HINT scores have fnat values close to 1 and those with lower scaled-HINT
scores have fnat values close to 0. We also checked the fnat values of top 10 and
lowest 10 HINT-ranked predictions for each test case. A total of n = 92 out of 150 (61%)
of the top 10 ranked predictions have a fnat value of ≥ 0.3 (one of the criteria for
medium accuracy, or better); with 10 out of 15 (67%) top ranked predictions having a
value of > 0.5 (high accuracy criteria) (Figure 4.4a). Also, a total of n = 112 out of 150
(75%) of the lowest 10 ranked predictions have a fnat value of < 0.3; with 12 out of the
15 (80%) lowest ranked predictions having a fnat value of < 0.1 (incorrect prediction)
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(Figure 4.4b). In addition, out of all the predictions with fnat value of 0, i.e. for all
predictions where not a single native residue-residue contact was identified, a total of n
= 622 out of 691 predictions (90%) have a scaled HINT score of < 0.5. In general, high
HINT-ranked predictions have fnat values close to 1 and vice versa – indicating the
utility of HINT scores as an effective filter for pose selection.

4.3.4 Unsolvated Docking vs Solvated Docking –
Despite the progress made in the development of protein-protein docking
programs, most predictions still lack considerable accuracy due to the complexity of the
problem. When compared to docking small molecules into a pocket, there are many
more degrees of freedom involved in bringing two proteins together. One of the most
critical factors that influence the assembly of proteins – water, is almost always ignored.
We believe that a protein-protein docking approach that explicitly accounts for interfacial
waters, correct ionization states of residue side-chains and extensive flexibility during
both the search and score stages will generate more accurate models.
To test the first of these, Relevant interfacial waters, i.e., “bridging” waters, were
identified for the 15 protein-protein complexes in the data-set using the HINT Relevance
Metric, and a rigid-body solvated docking was performed by forcing ZDOCK to include
“bridging” waters as atoms in the receptor protein. 100 solutions were generated for
every test case. The interfacial waters in every prediction were optimized for their
correct orientation using the HINT-based water-optimization algorithm. HINT interaction
scores were then calculated taking into account the energetic contribution of these
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Figure 4.3 – Scatterplot showing positive linear correlation between scaled HINT Scores and fnat values of all predictions
for each test case (n = 1500) (r = 0.307, p < 0.0001).
Predictions with high HINT scores have fnat values close to 1, and vice versa – indicating the ability of HINT to identify
correct poses. For clarity purposes, points with scaled HINT scores below -1.5 are not shown.
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Figure 4.4 – Scatterplot of fnat vs scaled HINT scores for top 10 and lowest 10
predictions.
(A) Scatterplot of fnat values vs scaled HINT scores for top 10 predictions of every test
case (n = 150). More than 60% of all top 10 predictions (92 out of 150) have fnat values
corresponding to medium accuracy or better models. The points shown in red are the
top predictions; 10 out of 15 have fnat values of > 0.5 – corresponding to high accuracy
prediction.
(B) Scatterplot of fnat values vs Scaled HINT scores for the lowest 10 predictions of
every test case (n = 150). 75% of all lowest 10 predictions (112 out of 150) have fnat
values corresponding to acceptable or incorrect models. The points shown in red are
the lowest ranked predictions; 12 out of 15 have fnat values < 0.1 – corresponding to
incorrect prediction.
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waters, and the predictions were ranked based on their scaled HINT scores. The
accuracy of the predictions was evaluated according to the standard CAPRI criteria
(Table 4.3), by computing three parameters – the fnat value, l-RMSD and i-RMSD; and
classified as incorrect, acceptable-accuracy, medium-accuracy and high-accuracy
models.
Two measures are calculated to compare the overall performance of unsolvated
and solvated docking over the entire data-set – average hit-count and weighted-score.
A prediction of medium accuracy or better was considered a hit and an average hitcount was calculated for the top N predictions. Also, every prediction was given a score
of 0, 1, 2 or 3 for incorrect, acceptable, medium or high accuracy, respectively. A total
weighted-score was calculated for the top N predictions of each test case.
Table 4.4 shows the hit-count for the top N predictions in case of unsolvated and
solvated docking. As it can be seen, solvated docking performs better overall than
unsolvated docking in terms of average hit-count. Especially in the top 10 predictions,
which are of more importance compared to lower ranked predictions, there was
significant improvement in the hit-count for each test case (paired t-test, p < 0.05)
(Figure 4.5), with an overall improvement of 24.72 % (7.40 for solvated docking,
compared to 5.93 for unsolvated docking) in the average hit-count. On comparing the
average hit-count for the top, top 10, top 25, top 50 and top 100 predictions, a
significant improvement (paired t-test, p < 0.05) was observed in the number of hits
generated for solvated docking (Table 4.5, Figure 4.6).
Table 4.6 shows the weighted-score for the top N predictions in the cases of
unsolvated and solvated docking. As can be seen, solvated docking performs better
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overall than unsolvated docking in terms of the quality of predictions. There was a
statistically significant improvement in the weighted-score for the top 10 predictions of
each test case (paired t-test, p < 0.05) (Figure 4.7), with an overall improvement of
22.94 % in the average weighted-score (17.87 for solvated docking, compared to 14.53
for unsolvated docking). Similar to the average hit-count, the average weighed-score for
top, top 10, top 25, top 50 and top 100 predictions showed statistically significant
improvement (paired t-test, p < 0.05) for solvated docking (Table 4.7, Figure 4.8). When
the number of high-accuracy predictions was compared (Table 4.8), similar
improvements were observed. Most notable was the improvement seen in the success
rate for the top ranked prediction: while the top prediction was a high-accuracy model
for just n = 2 out of 15 (13%) test cases for unsolvated docking, the top prediction was a
high-accuracy model for n = 6 out of 15 (40%) test cases for solvated docking. For the
top ranked model, the quality of the prediction improved from incorrect/medium
accuracy to high-accuracy for n = 5 out of total 15 (33%) test cases.
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Table 4.4 – Hit-count for top N predictions for different docking protocols

PDB ID

	
  

Unsolvated Docking

Solvated Docking

Top 1

Top 10

Top 25

Top 50

Top 100

Top 1

Top 10

Top 25

Top 50

Top 100

1avx

1

8

20

36

54

0

9

22

41

63

1clv

1

10

25

50

95

1

10

25

50

99

1dqj

0

1

10

16

16

0

8

19

31

32

1fle

1

5

5

5

5

1

5

8

9

9

1iqd

1

10

25

50

76

1

10

25

49

85

1jiw

0

4

15

25

32

1

7

17

27

33

1jps

0

0

1

1

1

0

2

2

2

2

1klu

1

2

2

2

2

1

4

5

5

5

1pxv

1

10

25

49

59

1

10

24

43

62

1r0r

0

0

0

0

13

0

0

0

0

25

1r8s

1

10

24

48

96

1

10

25

50

93

1wej

0

4

4

4

4

1

10

11

11

11

1zhh

1

6

8

9

9

1

7

16

20

20

2hqs

1

9

16

19

19

1

9

16

18

18

2sic

1

10

24

47

74

1

10

22

46

72

150

Table 4.5 – Comparison of average hit-count for different docking protocols

Docking
Protocol

Total hit-count

n

Top N Predictions

(testcases)

1

10

25

50

100

Unsolvated

15

10

89

204

361

555

Solvated

15

11

111

237

402

629

1

22

33

41

74

Unsolvated

0.67

5.93

13.60

24.07

37.00

Solvated

0.73

7.40

15.80

26.80

41.93

0.07

1.47

2.20

2.73

4.93

Difference
Average hitcount
Difference
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Figure 4.5 a – Number of hits in the top N predictions in unsolvated and solvated docking
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Figure 4.5 b – Difference in number of hits in the top N predictions in unsolvated and solvated docking for each test case.
(Δ = Nsolvated – Nunsolvated).
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Figure 4.6 – Comparison of average hit-count in top N predictions for unsolvated and
solvated docking.
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Table 4.6 – Weighted-score for top N predictions for different docking protocols

PDB ID

	
  

Unsolvated Docking

Solvated Docking

Top 1

Top 10

Top 25

Top 50

Top 100

Top 1

Top 10

Top 25

Top 50

Top 100

1avx

2

19

48

93

143

1

19

52

97

155

1clv

3

30

75

149

284

3

30

75

150

296

1dqj

0

2

24

36

39

0

18

43

69

72

1fle

2

14

14

14

15

3

15

24

27

28

1iqd

2

23

59

112

170

2

21

56

109

188

1jiw

0

10

37

63

79

2

17

41

68

80

1jps

0

0

3

3

3

0

4

4

4

4

1klu

3

6

6

6

6

3

12

16

16

16

1pxv

2

21

51

101

122

2

21

49

91

130

1r0r

0

0

0

0

37

0

0

0

0

71

1r8s

2

20

49

97

196

2

20

51

102

189

1wej

0

10

13

14

14

3

26

32

35

36

1zhh

2

14

18

20

20

2

14

33

41

41

2hqs

2

23

40

49

49

3

23

40

45

45

2sic

2

26

60

112

190

3

28

59

113

189

155

Table 4.7 – Comparison of average weighted-score for different docking protocols

Docking
Protocol

Total weighted-score

score
Difference

	
  

(testcases)

Top N Predictions
1

10

25

50

100

Unsolvated

15

22

218

497

869

1367

Solvated

15

29

268

575

967

1540

7

50

78

98

173

Unsolvated

1.47

14.53

33.13

57.93

91.13

Solvated

1.93

17.87

38.33

64.47

102.67

0.47

3.33

5.20

6.53

11.53

Difference
Average weighted-

n
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Figure 4.7 a – Weighted – Score for the top N predictions in unsolvated and solvated docking
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Figure 4.7 b – Difference in weighted-score for top N predictions in unsolvated and solvated docking for each test case.
(Δ = Ssolvated – Sunsolvated).
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Figure 4.8 – Comparison of average weighted – score for top N predictions for
unsolvated and solvated docking.
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Table 4.8 – Count of high-accuracy (***) models in top N predictions
PDB ID

Top 1 Top 10 Top 25 Top 50

Solvated Docking
Top 100

Top 1 Top 10 Top 25 Top 50

Top 100

1avx

0

1

3

7

8

0

0

5

6

7

1clv

1

10

25

49

94

1

10

25

50

98

1dqj

0

0

4

4

4

0

2

5

7

7

1fle

0

4

4

4

4

1

5

8

9

9

1iqd

0

3

9

12

16

0

1

6

10

14

1jiw

0

0

4

9

9

0

2

5

11

11

1jps

0

0

1

1

1

0

0

0

0

0

1klu

1

2

2

2

2

1

4

5

5

5

1pxv

0

1

1

3

3

0

1

1

5

6

1r0r

0

0

0

0

11

0

0

0

0

21

1r8s

0

0

0

0

3

0

0

1

2

2

1wej

0

2

2

2

2

1

6

6

6

6

1zhh

0

2

2

2

2

0

0

1

1

1

2hqs

0

5

8

11

11

1

5

8

9

9

2sic

0

6

12

18

19

1

8

15

20

21

Total

2

36

77

124

189

6

44

91

141

217

0.13

2.40

5.13

8.27

12.60

0.40

2.93

6.07

9.40

14.47

Average
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The comparison between the predictions obtained from both docking protocols
show that there is a significant improvement in the total number of hits and the quality of
predictions for solvated docking. This trend indicates that more accurate and reliable
results are obtained when bridging interfacial waters are not ignored.

	
  

161

4.4 Discussion

Detailed analysis of protein-protein complexes has revealed that water molecules
form hydrogen bonds with interfacial side-chains, mediating and stabilizing the
biomolecular association. Most water molecules are not randomly trapped in the
protein–protein interface, but are part of the recognition code facilitating interactions that
are less favorable in its absence.78 However, most current docking programs only take
into account the underlying physics of protein-protein interactions, ignoring the role of
water molecules. The conformational search step of the docking process is generally
performed in vacuum, not accounting for the presence of water molecules. Some
docking algorithms incorporate a desolvation term in their scoring functions, implicitly
accounting for water. This improves the ranking of docked predictions and subsequent
identification of correct configuration.79 However, implicit treatment of waters introduces
approximations and the description of energetics is coarser than explicit models.
In the current study, we demonstrated that water can be explicitly introduced into
protein-protein docking protocols. Using HINT-based tools to identify Relevant bridging
water molecules and incorporating them into the docking protocol improves the quality
of predictions. Figure 4.9 shows the plot of i-RMSD vs scaled HINT scores for all
predictions obtained by our solvated docking protocol, grouped based on quality. A total
of n = 111 out of 150 (74%) top 10 predictions were of medium accuracy or better
(Table 4.5); showing improvements in not only the number of hits, but also in scoring
with high/medium accuracy models ranking much better than incorrect ones.
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Figure 4.9 – Scatterplot of i-RMSD vs scaled HINT Scores for all predictions obtained from solvated docking, grouped
based on their quality.
On average, predictions of high/medium accuracy rank much better than the incorrect ones.
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We can now illustrate how docking results improve when a solvated docking
approach is applied, using as an example the anti-lysozyme antibody HyHEL-63
complexed with hen egg white lysozyme HEL (test case # 3, PDB ID: 1dqj). The crystal
structure of the complex has been determined at 2.0 Å resolution, with the presence of
17 interfacial waters (within 4.0 Å of both molecules).80 The orientation of each water
molecule was optimized using the HINT-based optimization algorithm, as described
before. The relevance of these waters was determined using HINT Relevance metric,
which identified 7 waters to be Relevant to both proteins forming bridging interactions
with interfacial residues (Table 4.9, Figure 4.10). The individual proteins were separated
from the complex structure and subsequently docked using both the unsolvated and
solvated docking protocols; the 7 bridging waters were considered as a part of receptor
protein for the latter. As described before, the predictions were ranked based on their
HINT interaction scores and also evaluated for accuracy based on standard CAPRI
criteria.
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Table 4.9 – HINT Water Relevance Report for interfacial waters* in Anti-Lyzozyme Antibody HyHEL-63 – Lyzozyme HEL
complex crystal structure (test case #3, PDB ID – 1dqj).
Target Two -Lyzozyme
Target One - Anti-Lyzozyme
HEL
Antibody HyHEL-63
Monomer
Water #
Name
Chain A/B
Chain C
Rank
Score
Relevance
Rank
Score
Relevance
1
HOH130
4.19
68.60
0.65
1.51
72.20
0.37
2

HOH131

1.26

122.40

0.39

2.34

-314.10

-0.47

3

HOH133

2.74

124.60

0.56

2.78

-36.50

0.39

4

HOH134

1.03

-5.70

0.25

2.58

-218.80

-0.24

5

HOH138

1.42

-58.90

0.21

3.59

-195.60

-0.19

6

HOH140

0.00

-64.00

-0.04

2.21

196.70

0.57

7

HOH141

2.50

48.70

0.45

1.32

16.80

0.30

8

HOH143

1.44

117.60

0.41

3.92

48.20

0.62

9

HOH146

0.90

-42.40

0.20

1.20

272.00

0.44

10

HOH152

1.03

-43.40

0.22

1.14

121.50

0.36

11

HOH182

2.40

123.30

0.52

1.32

29.50

0.31

12

HOH222

3.00

270.70

0.71

2.85

113.00

0.55

13

HOH243

1.02

-78.60

0.19

1.08

116.60

0.35

14

HOH263

1.13

60.30

0.32

0.00

-153.80

-0.07

15

HOH327

0.96

7.00

0.24

0.93

42.50

0.27

16

HOH335

1.03

166.90

0.34

0.00

-79.10

-0.04

17
HOH388
1.11
43.70
0.30
0.92
*Relevant/bridging waters (having relevance ≥ 0.25 for both proteins) are shown in bold.

36.50

0.26
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Figure 4.10 – (Top) Crystal Structure of Anti-Lysozyme Antibody HyHEL-63 (green) –
Lysozyme HEL (cyan) complex (PDB ID: 1dqj). The image shows the presence of
Relevant interfacial waters (red spheres). (Bottom) Detailed view of the interface
showing bridging interactions of Relevant waters with residues on both proteins.
Image prepared using PyMOL.81
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In the case of unsolvated docking, a total of n = 16 out of 100 (proportion = 0.16)
predictions were of medium accuracy or better (Table 4.4), with just one prediction of
medium accuracy (rank = 10) within the top 10. Clustering the top 10 predictions
showed three different poses for the ligand proteins – Cluster 1 consisting of n = 5
predictions (rank – 1, 2, 3, 4, 8) was an incorrect pose; Cluster 2 consisting of n = 4
predictions (rank – 5, 6, 7, 9) was also an incorrect pose; Cluster 3 consisting of n = 1
prediction (rank – 10) was a medium accuracy pose (Table 4.10). Solvated docking, on
the other hand, resulted in n = 32 (proportion = 0.32) predictions of medium accuracy or
better (Table 4.4). More notable was the improvement in the accuracy of the top 10
predictions. Clustering showed two different poses – Cluster 1 consisting of n = 2
predictions (rank – 1, 3) was an incorrect pose; while Cluster 2 consisting of the
remaining n = 8 predictions was the native-like pose, with 6 predictions of medium
accuracy and 2 predictions (rank – 7, 8) of high-accuracy (Table 4.11)
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Table 4.10 – Unsolvated docking results for HyHEL-63 – HEL complex

Prediction

HINT
Score

Scaled
HINT
Score

Rank

i-RMSD

l-RMSD

fnat

Cluster/
Pose

Model
Quality

Hit

model 1

4805.926

1.000

1

8.549

11.004

0.127

1

-

n

model 2

4355.065

0.906

2

9.864

12.264

0.113

1

-

n

model 3

4236.699

0.882

3

9.806

12.167

0.127

1

-

n

model 4

4124.475

0.858

4

8.835

11.374

0.127

1

-

n

model 5

4115.901

0.856

5

7.954

12.733

0.028

2

-

n

model 6

4105.278

0.854

6

8.256

13.208

0.028

2

-

n

model 7

4036.962

0.840

7

8.388

13.442

0.028

2

-

n

model 8

3880.502

0.807

8

9.573

12.326

0.141

1

-

n

model 9

3835.744

0.798

9

8.235

13.061

0.014

2

-

n

model 10

3796.472

0.790

10

1.716

2.321

0.915

3

**

y

Top 10 predictions, ranked based on their HINT scores. i-RMSD, l-RMSD and fnat values calculated against the complex
crystal structure. Three clusters/poses for the ligand protein (within 2.0 Å of each other) were seen within the top 10
models, as indicated by the number. Asterisks in the model quality column correspond to CAPRI quality criteria – high
accuracy (***), medium accuracy (**), acceptable (*) and incorrect (-). Hit – a prediction with medium accuracy or better.
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Table 4.11 – Solvated docking results for HyHEL-63 – HEL complex

Prediction

HINT
Score

Scaled
HINT
Score

Rank

i-RMSD

l-RMSD

fnat

Cluster/
Pose

Model
Quality

Hit

model 1

6098.512

1.000

1

6.436

7.036

0

1

-

n

model 2

5327.556

0.874

2

1.617

2.223

0.944

2

**

y

model 3

5045.993

0.827

3

7.194

7.474

0

1

-

n

model 4

4982.928

0.817

4

1.497

1.208

0.986

2

**

y

model 5

4855.246

0.796

5

1.079

1.305

0.958

2

**

y

model 6

4852.371

0.796

6

1.049

2.931

0.761

2

**

y

model 7

4774.186

0.783

7

0.948

1.717

0.901

2

***

y

model 8

4715.043

0.773

8

0.899

0.640

0.958

2

***

y

model 9

4638.276

0.761

9

2.480

2.463

0.873

2

**

y

model 10

4634.395

0.760

10

1.414

3.055

0.775

2

**

y

Top 10 predictions, ranked based on their HINT scores. i-RMSD, l-RMSD and fnat values calculated against the complex
crystal structure. Two clusters/poses for the ligand protein (within 2.0 Å of each other) were seen within the top 10 models,
as indicated by the number. Asterisks in the model quality column correspond to CAPRI quality criteria – high accuracy
(***), medium accuracy (**), acceptable (*) and incorrect (-). Hit – a prediction with medium accuracy or better.
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These improvements in the solvated docking results can be attributed to the
presence of water molecules that change the physical and chemical properties of the
receptor protein interface. For instance, water HOH143 is involved in bridging
interactions between B/Tyr58 of HyHEL-63 (receptor protein) and C/Val99 and
C/Asp101 of HEL (ligand protein), as seen in the crystal structure (Figure 4.11). In
unsolvated docking, because of the absence of an explicit water molecule near B/Tyr58,
the region is occupied by residues of ligand protein – C/Gly22 in cluster 1 and C/Gln57
in cluster 2, forming direct polar interactions with the Tyr –OH group and resulting in
non-native like predictions. For cluster 3, a native like prediction with medium accuracy
was generated, although the interaction between B/Tyr58 and C/Val99 is not observed
(Figure 4.12). But when docking is performed using the solvated docking protocol, the
presence of water HOH143 molecule results in better shape and hydropathic
complementarity with the ligand surface and thereby leads to more accurate native-like
predictions – cluster 2 retaining the water-mediated interaction between B/Tyr58 and
C/Val99, as seen in the crystal structure. (Figure 4.13)
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Figure 4.11 – Bridging interactions formed by Relevant interfacial water HOH 143 with
Tyr58 of HyHEL-63 (receptor protein, green surface) and Val99 and Asp101 of HEL
(ligand protein, cyan surface) observed in the crystal structure of the complex (PDB ID:
1dqj). Image prepared using PyMOL.
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Figure 4.12 – Unsolvated docking results for HyHEL-63 – HEL complex.
The left panel for each cluster shows the overlay of predicted ligand pose (cyan
cartoon) with the crystal structure (red cartoon). Only cluster 3 (n = 1 prediction) was a
medium-accuracy native-like prediction. The right panel focuses on the interactions of
B/Tyr58 with ligand residues. For cluster 1 and cluster 2, native residue-residue
contacts are not retained, corresponding to incorrect predictions.
Image prepared using PyMOL.
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Figure 4.13 – Solvated docking results for HyHEL-63 – HEL complex.
The left panel for each cluster shows the overlay of predicted ligand pose (cyan
cartoon) with the crystal structure (red cartoon). Majority of top 10 predictions (n = 8)
were native-like predictions.
The right panel focuses on the bridging interactions of HOH143 with receptor and ligand
residues. For cluster 1, non-native like prediction was generated showing watermediated interaction between B/Tyr58 and C/Lys116. For cluster 2 (that consists of
majority of top 10 predictions, n = 8), native water-mediated residue-residue contacts
are retained, with B/Tyr58 showing water-mediated hydrogen-bonding network with
C/Val99 and C/Asp101.
Image prepared using PyMOL.
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Such results indicate that our solvated docking protocol, which utilizes HINTbased tools, can be successfully used for improving protein-protein docking results. A
significant improvement in the quality of top predictions indicates that HINT scoring
function can effectively discriminate between poses and suggests that scoring can be
improved when waters are explicitly accounted for.
Even so, this approach is woefully crude because water is represented as only a
single atom during the search stage and does not really reproduce its chemical
properties. It is only during the scoring stage, when protons are added and water
molecules are optimized, that the complete set of properties for the waters are
incorporated. Since the HINT scoring function has shown to effectively identify nativelike poses from incorrect ones, even greater improvements can be expected if we can
introduce HINT scoring in the conformational space search to ascertain the viability of a
particular pose. This will result in more accurate predictions to proceed to the
subsequent refinement and scoring stages, overall improving the success rate of the
docking algorithm.
Our current study focused on understanding the direct influence of interfacial
water on the quality of structure prediction for protein-protein complexes. For this
purpose, we performed a bound-bound docking, which means the starting structures of
the proteins were obtained from the crystal structure of the bound complex. This
eliminates two major issues that might result in incorrect predictions – protein flexibility
associated with unbound docking and positions of Relevant water molecules. Ideally,
we would like to like to start with unbound structures of the interacting partners and try
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to predict the bound form, but this is a more difficult problem as it adds many more
degrees of freedom to an already spectacularly under determined problem.
The HINT forcefield and ancillary tools like the HINT water relevance metric,
HINT-based computational titration and a novel HINT map based 3D refinement
algorithm can be successfully used to model the hydropathic complementarity, the
positions of Relevant interfacial waters, the correct ionization states of interfacial
residues and interfacial protein flexibility, respectively. With appropriate refinements, a
novel HINT-based docking approach can be designed that can accurately model
protein-protein complexes.
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4.5 Conclusion
Characterizing the nature of interactions between proteins that have not been
experimentally co-crystallized requires a docking approach that can successfully predict
the spatial conformation adopted in the complex. Interfacial waters contribute
immensely to the kinetics and thermodynamics underlying protein-protein interactions.
In this chapter, we have demonstrated the utility of HINT scoring and other
computational tools based off it towards structural prediction of protein-protein
complexes, by explicitly accounting for interfacial waters that are generally ignored in
the current docking programs. We have shown that using hydropathic complementarity
and not ignoring these Relevant waters in the modeling of protein complexes does show
an statistically significant improvement in the quality of predictions generated by the
docking algorithm. The analysis of illustrative example of anti-lysozyme – lysozyme
complex revealed that certain binding modes that would otherwise be ranked higher can
be eliminated by the steric presence of water molecules. Also, the explicit presence of
interfacial waters may result in additional hydrogen bond interactions, improving the
energy scores, and thereby ranking the correct binding modes higher.
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CHAPTER 5
CONCLUSIONS

Substantive progress is being made in the atomic and residue level
understanding of biomolecular interactions. Computational tools that provide a
quantitative assessment of the energetic contributions of individual interactions involved
in molecular recognition have been extensively used in drug design and development
process. An empirical HINT force field for quantifying non-covalent interactions,
correlating with the ∆𝑮𝒊𝒏𝒕𝒆𝒓𝒂𝒄𝒕𝒊𝒐𝒏 , has been developed by Kellogg and Abraham, based
on experimental partition coefficient 𝐿𝑜𝑔𝑃!/! data.1 Being derived from an experimental
thermodynamic parameter ( 𝐿𝑜𝑔𝑃!/! ), HINT is advantageous over other force
fields/scoring functions because it accounts not only for the electrostatic, Coulombic,
van der Waal’s and hydrophobic interactions, but also implicitly takes into consideration
the contributions of entropy and solvation/desolvation processes towards the binding
event. The implementation of HINT force field and various tools based off it has led to
better

understanding

of

the

protein-ligand,

protein-protein

and

protein-DNA

associations.2-4 In this dissertation, we have discussed the use of HINT force field in

	
  

183

molecular modeling studies for novel anticancer and antiviral targets, as well as in
developing a novel solvated protein-protein docking protocol.
In our efforts to gain structural insights into the isoform selectivity of a
thiazolidine-2,4-dione analog (K145) towards Sphingosine kinase 2, an anti-cancer
target, we successfully built structural models of both isoforms of sphingosine kinase
(SphK1 and SphK2) using the crystal structure of a kinase of bacterial origin as the
template. This was followed by molecular docking of the ligand in the sphingosinebinding domains of both kinases. The analysis of proposed binding modes using HINT
force field suggested that K145 binds more favorably to SphK2, but not SphK1,
consistent with the biochemical assay results. We understand that the protein models
and ligand binding modes have not been experimentally validated, and therefore should
be used with caution. However, in absence of a crystallographic structure, the models
can be used as hypothesis generator for future lead optimization and compound design
efforts towards developing thiazolidine-based inhibitors as anti-cancer agents.5
The structural modeling of Human Cytomegalovirus (HCMV) Alkaline Nuclease
(AN) UL98 has also been discussed in the dissertation. A similar homology-based
modeling of UL98 AN was performed, using the crystal structure of a homologous
exonuclease from another herpesvirus as the template, in order to identify active-site
residues involved in its nucleolytic activity that are very important for viral replication.
Again, hydropathic analysis of the protein-DNA complex using HINT force field identified
the key residues: R164, S252, D254, E278 and K280 that showed significant
interactions with 5’ end of DNA, to be important for its exo- and/or endo- nuclease
activity. Mutagenesis studies were performed to validate the model, with alanine
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substitutions abolishing activity. The results confirm the utility of the model in
representing the active site region of UL98 AN.6 The protein-DNA complex model was
then used to build a pharmacophore model complimentary to the protein active site, to
virtually screen the NCI database of ~250,000 compounds. Molecular docking and
subsequent scoring (using HINT force field) of the hits, yielded a number of novel
interesting compounds, which have the potential to bind at UL98 AN active site and
inhibit it. Top 15 compounds have been obtained from the vendor and are currently
being evaluated experimentally. The use of an experimentally validated protein model
and HINT scoring for identifying top hits, gives us confidence that our approach might
result in identification of novel antiviral agents.
Finally, we have addressed the issue of explicit solvent accounting in proteinprotein docking algorithms. Several studies, using HINT based tools, have shown the
importance

of

water

molecules

at

interfaces,

in

mediating

and

stabilizing

biomacromolecular associations.7-10 Majority of the current protein-protein docking
approaches only implicitly incorporate the effects of solvent by introducing the
desolvations terms in their scoring functions, which might be one of the reason for
considerable lack in prediction accuracy. We hypothesize that docking algorithms that
explicitly account for water at interface with yield more native-like models. On a data-set
of 15 protein-protein complex crystal structures, we identified those waters that showed
bridging interactions between both interacting partners, using the HINT Water
Relevance Metric. We developed a solvated docking protocol – wherein the relevant
waters were forced to be a part of one of the two proteins, followed by rigid-body
docking using ZDOCK,11 and ranking the predictions using HINT energy scores. The
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predictions were checked for accuracy using the standard CAPRI criteria.12 Comparing
the results of solvated docking approach with a traditional unsolvated one, we have
shown considerable improvement in the quality of predictions obtained. Our
implementation of HINT based tools to the docking protocol is still at the simplest level,
with complete chemical properties of waters being utilized only at the scoring stage.
Even so, our study shows promise. It is safe to say that we can expect considerably
higher prediction accuracy with further attempts to optimize the protein-protein docking
algorithms by incorporating not just hydropathic complementarity, but also explicit
solvent accounting, correct interfacial residue ionization states, and interfacial sidechain flexibility. This study is just a beginning of the ultimate goal of our lab – to develop
a protein-protein docking algorithm based on HINT tools.
To summarize, the overall goal of this multidisciplinary work was the application
of HINT force field and HINT-based tools to different aspects of molecular modeling –
from structural modeling of novel anticancer and antiviral targets, to explicit solvent
accounting in a protein-protein docking approach. The results of this research will
provide the scientific community with additional knowledge to better predict and model
biomacromolecular structures.
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APPENDIX A.1
Clustal X default color scheme
Residue at

Color

{Threshold, Residue group}

A,I,L,M,F,M,V

Blue

{+60%, WLVIMAFCHP)

R,K

Red

{+60%, KR}, {+80%, KRQ}

N

Green

{+50%, N}, {+85%, NY}

C

Blue

{+60%, WLVIMAFCHP)

C

Pink

{100%, C}

Q

Green

{+60%, KR}, {+50%, QE}, {+85%, QEKR}

E

Magenta

{+60%, KR}, {+50%, QE}, {+85%, EQD}

D

Magenta

{+60%, KR}, {+85%, KRQ}, {+50%, ED}

G

Orange

{+0%, G}

H,Y

Cyan

{+60%, WLVIMAFCHP}, {+85%, WYACPQFHILMV}

P

Yellow

{+0%, P}

S,T

Green

{+60%, WLVIMAFCHP}, {+50%, TS}, {+85%, ST}

position

Each residue in the alignment is assigned a color if the amino acid profile of the
alignment at that position meets the minimum criteria specific for the residue type.
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